| 440 Publications |
This is a list of publications by this researcher, listed chronologically starting with the most recent first. New publications appear in this list weekly. The source of publications and 'cited by' data for this application is Scopus.
Export
-
1.
2013Fa-Zhong He; Howard L. McLeod; Wei Zhang
Current pharmacogenomic studies on hERG potassium channels
Trends in Molecular Medicine. 2013;19(4):227-238.0 -
2.
2013Stefanie D. Krens; Howard L. McLeod; Daniel L. Hertz
Pharmacogenomics. 2013;14(5):555-574.0 -
3.
2013Malin L. Appell; Jonathan Berg; John Duley; William E. Evans; Martin A. Kennedy; Lynne Lennard; Tony Marinaki; Howard L. McLeod; Mary V. Relling; Elke Schaeffeler; et al.
Nomenclature for alleles of the thiopurine methyltransferase gene
Pharmacogenetics and Genomics. 2013;23(4):242-248.0 -
4.
2013Howard L. McLeod
Cancer pharmacogenomics: Early promise, but concerted effort needed
Science. 2013;340(6127):1563-1566.2 -
5.
2013David Gurwitz; Howard L. McLeod
Genome-wide studies in pharmacogenomics: Harnessing the power of extreme phenotypes
Pharmacogenomics. 2013;14(4):337-339.0 -
6.
2013Michelle A. Rudek; Roisin M. Connolly; Janelle M. Hoskins; Elizabeth Garrett-Mayer; Stacie C. Jeter; Deborah K. Armstrong; John H. Fetting; Vered Stearns; Laurie A. Wright; Ming Zhao; et al.
Breast Cancer Research and Treatment. 2013:1-9.0 -
7.
2013Morgan Trammel; Mary Roederer; Jai Patel; Howard McLeod
Current Oncology Reports. 2013:1-10.0 -
8.
2013Lionel D. Lewis; Antonius A. Miller; Kouros Owzar; Robert R. Bies; Svetlana Markova; Chen Jiang; Deanna L. Kroetz; Merrill J. Egorin; Howard L. McLeod; Mark J. Ratain
Pharmacogenetics and Genomics. 2013;23(1):29-33.0 -
9.
2013Brian C Jensen; Howard L McLeod
Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity
Pharmacogenomics. 2013;14(2):205-213.0 -
10.
2012Chad C. Brown; Tammy M. Havener; Marisa Wong Medina; Ronald M. Krauss; Howard L. McLeod; Alison A. Motsinger-Reif
BioData Mining. 2012:21.0 -
11.
2012Chad C. Brown; Tammy M. Havener; Marisa W. Medina; J. Todd Auman; Lara M. Mangravite; Ronald M. Krauss; Howard L. McLeod; Alison A. Motsinger-Reif
Pharmacogenetics and Genomics. 2012;22(11):796-802.3 -
12.
2012Yi Jing He; Anne D. Misher; William Irvin; Alison Motsinger-Reif; Howard L. McLeod; Janelle M. Hoskins
Assessing the utility of whole genome amplified DNA as a template for DMET Plus array
Clinical Chemistry and Laboratory Medicine. 2012;50(8):1329-1334.0 -
13.
2012Y.J. He; H.L. McLeod
Ready When You Are: Easing into Preemptive Pharmacogenetics
Clinical Pharmacology and Therapeutics. 2012;92(4):412-414.2 -
14.
2012R. Michael Baldwin; Kouros Owzar; Hitoshi Zembutsu; Aparna Chhibber; Michiaki Kubo; Chen Jiang; Dorothy Watson; Rachel J. Eclov; Joel Mefford; Howard L. McLeod; et al.
Clinical Cancer Research. 2012;18(18):5099-5109.7 -
15.
2012Yusuke Nakamura; Mark J. Ratain; Nancy J. Cox; Howard L. McLeod; Deanna L. Kroetz; David A. Flockhart
Journal of the National Cancer Institute. 2012;104(16):1264.8 -
16.
2012Janelle M. Hoskins; Pei-Shi Ong; Temitope O. Keku; Joseph A. Galanko; Christopher F. Martin; Clint A. Coleman; Michelle Wolfe; Robert S. Sandler; Howard L. McLeod
PLoS ONE. 2012;7(7).0 -
17.
2012Howard L. McLeod; Yijing He
Pharmacokinetics for the prescriber
Medicine (United Kingdom). 2012;40(7):357-361.0 -
18.
2012Daniel L. Hertz; Alison A. Motsinger-Reif; Amy Drobish; Stacey J. Winham; Howard L. McLeod; Lisa A. Carey; E. Claire Dees
CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel
Breast Cancer Research and Treatment. 2012;134(1):401-410.3 -
19.
2012R.A. Wilke; L.B. Ramsey; S.G. Johnson; W.D. Maxwell; H.L. McLeod; D. Voora; R.M. Krauss; D.M. Roden; Q. Feng; R.M. Cooper-Dehoff; et al.
Clinical Pharmacology and Therapeutics. 2012;92(1):112-117.11 -
20.
2012James J. Crowley; Yunjung Kim; Jin Peng Szatkiewicz; Amanda L. Pratt; Corey R. Quackenbush; Daniel E. Adkins; Edwin Van Den Oord; Molly A. Bogue; Hyuna Yang; Wei Wang; et al.
Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice
Mammalian Genome. 2012;23(5-6):322-335.2 -
21.
2012Shanna K. O'Connor; Stefanie P. Ferreri; Natasha M. Michaels; Angelo J. Greco; Anthony J. Viera; Hawazin Faruki; Howard L. McLeod; Mary W. Roederer
Exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy
Pharmacogenomics. 2012;13(8):955-962.1 -
22.
2012Christine M. Walko; Howard McLeod
Use of CYP2D6 genotyping in practice: Tamoxifen dose adjustment
Pharmacogenomics. 2012;13(6):691-697.2 -
23.
2012J.J. Crowley; D.E. Adkins; A.L. Pratt; C.R. Quackenbush; E.J. Van Den Oord; S.S. Moy; K.C. Wilhelmsen; T.B. Cooper; M.A. Bogue; H.L. McLeod; et al.
Pharmacogenomics Journal. 2012;12(2):147-155.0 -
24.
2012Yi Jing He; Michael H. Shapero; Howard L. Mcleod
Pharmacogenetics and Genomics. 2012;22(4):322-324.1 -
25.
2012Jasmine A. Talameh; Howard L. McLeod; Kirkwood F. Adams Jr.; J. Herbert Patterson
Journal of Cardiac Failure. 2012;18(4):338-349.0 -
26.
2012Hong-Hee Won; Suk Ran Kim; Oh Young Bang; Sang-Chol Lee; Wooseong Huh; Jae-Wook Ko; Hyung-Gun Kim; Howard L. McLeod; Thomas M. O'Connell; Jong-Won Kim; et al.
Differentially expressed genes in human peripheral blood as potential markers for statin response
Journal of Molecular Medicine. 2012;90(2):201-211.1 -
27.
2012Federico Innocenti; Kouros Owzar; Nancy L. Cox; Patrick Evans; Michiaki Kubo; Hitoshi Zembutsu; Chen Jiang; Donna Hollis; Taisei Mushiroda; Liang Li; et al.
Clinical Cancer Research. 2012;18(2):577-584.8 -
28.
2012Daniel L. Hertz; Howard L. McLeod; William J. Irvin Jr.
Tamoxifen and CYP2D6: A contradiction of data
Oncologist. 2012;17(5):620-630.7 -
29.
2012Rajesh R. Kaldate; Abebe Haregewoin; Charles E. Grier; Stephanie A. Hamilton; Howard L. McLeod
Oncologist. 2012;17(3):296-302.1 -
30.
2012Kevin C Brown; Mina C Hosseinipour; Janelle M Hoskins; Ranjit K Thirumaran; Hsiao-Chuan Tien; Ralf Weigel; Jean Tauzie; Ida Shumba; Jatinder K Lamba; Erin G Schuetz; et al.
Pharmacogenomics. 2012;13(1):113-121.3 -
31.
2011J.A. Talameh; H.L. McLeod
PON1 Q192R and clopidogrel: A case of the winners curse or inadequate replication?
Clinical Pharmacology and Therapeutics. 2011;90(6):771-774.1 -
32.
2011F. Thomas; A.A. Motsinger-Reif; J.M. Hoskins; A. Dvorak; S. Roy; A. Alyasiri; R.J. Myerson; J.W. Fleshman; B.R. Tan; H.L. McLeod
British Journal of Cancer. 2011;105(11):1654-1662.6 -
33.
2011Mary W. Roederer; HowardLeod McLeod; Jonathan J. Juliano
Can pharmacogenomics improve malaria drug policy?
Bulletin of the World Health Organization. 2011;89(11):838-845.1 -
34.
2011Venita Gresham Watson; Nicholas E. Hardison; Tyndall Harris; Alison Motsinger-Reif; Howard L. McLeod
Genomic profiling in CEPH cell lines distinguishes between the camptothecins and indenoisoquinolines
Molecular Cancer Therapeutics. 2011;10(10):1839-1845.2 -
35.
2011Torben S. Mikkelsen; Caroline F. Thorn; Jun J. Yang; Cornelia M. Ulrich; Deborah French; Gianluigi Zaza; Henry M. Dunnenberger; Sharon Marsh; Howard L. McLeod; Kathy Giacomini; et al.
PharmGKB summary: Methotrexate pathway
Pharmacogenetics and Genomics. 2011;21(10):679-686.5 -
36.
2011Eric J Peters; Alison Motsinger-Reif; Tammy M. Havener; Lorraine Everitt; Nicholas E. Hardison; Venita G. Watson; Michael Wagner; Kristy L. Richards; Mike A. Province; Howard L. McLeod
Pharmacogenomic characterization of US FDA-approved cytotoxic drugs
Pharmacogenomics. 2011;12(10):1407-1415.10 -
37.
2011Janna E. Hutz; W. Aaron Manning; Michael A. Province; Howard L. McLeod
PLoS ONE. 2011;6(9).1 -
38.
2011William J. Irvin Jr.; Christine M. Walko; Karen E. Weck; Joseph G. Ibrahim; Wing K. Chiu; E. Claire Dees; Susan G. Moore; Oludamilola A. Olajide; Mark L. Graham; Sean T. Canale; et al.
Journal of Clinical Oncology. 2011;29(24):3232-3239.33 -
39.
2011Y. He; S.J. Wood; J. Paul; A. Motsinger-Reif; T. Auman; J.M. Hoskins; R. Brown; H.L. McLeod
Clinical Pharmacology and Therapeutics. 2011;90(2):344.0 -
40.
2011Caroline F. Thorn; Connie Oshiro; Sharon Marsh; Tina Hernandez-Boussard; Howard McLeod; Teri E. Klein; Russ B. Altman
Doxorubicin pathways: Pharmacodynamics and adverse effects
Pharmacogenetics and Genomics. 2011;21(7):440-446.6 -
41.
2011Howard L. Mcleod; Kim L. Isaacs
Preemptive pharmacogenetic testing: Insufficient data equal unsatisfactory guidance
Annals of Internal Medicine. 2011;154(12):842-843.4 -
42.
2011Paula M. Fracasso; Kerry J. Williams; Ronald C. Chen; Joel Picus; Cynthia X. Ma; Matthew J. Ellis; Benjamin R. Tan; Timothy J. Pluard; Douglas R. Adkins; Michael J. Naughton; et al.
Cancer Chemotherapy and Pharmacology. 2011;67(6):1225-1237.13 -
43.
2011Jill M. Kolesar; Suzanne E. Dahlberg; Sharon Marsh; Howard L. McLeod; David H. Johnson; Steven M. Keller; Joan H. Schiller
Oncology Reports. 2011;25(6):1765-1772.0 -
44.
2011Mary W Roederer; Francisco Sanchez-Giron; Kusha Kalideen; William Kudzi; Howard L McLeod; Wei Zhang
Pharmacogenetics and rational drug use around the world
Pharmacogenomics. 2011;12(6):897-905.2 -
45.
2011Yijing He; Janelle M. Hoskins; Howard L. McLeod
Copy number variants in pharmacogenetic genes
Trends in Molecular Medicine. 2011;17(5):244-251.7 -
46.
2011Luciano Carvalho; Jinsheng Yu; Gilberto Schwartsmann; Howard L. McLeod; James W. Fleshman
RNA expression of the molecular signature genes for metastasis in colorectal cancer
Oncology Reports. 2011;25(5):1321-1327.0 -
47.
2011Caroline F. Thorn; Sharon Marsh; Michelle Whirl Carrillo; Howard L. McLeod; Teri E. Klein; Russ B. Altman
Pharm GKB summary: Fluoropyrimidine pathways
Pharmacogenetics and Genomics. 2011;21(4):237-242.4 -
48.
2011Liewei Wang; Howard L. McLeod; Richard M. Weinshilboum
New England Journal of Medicine. 2011;364(12):1144-1153.111 -
49.
2011Filipe A. Muhale; Barbara A. Wetmore; Russell S. Thomas; Howard L. McLeod
Systems pharmacology assessment of the 5-fluorouracil pathway
Pharmacogenomics. 2011;12(3):341-350.1 -
50.
2011Roshawn G. Watson; Howard L. McLeod
Pharmacogenomic contribution to drug response
Cancer Journal. 2011;17(2):80-88.8 -
51.
2011Lisa Padgett; Shanna O'Connor; Mary Roederer; Howard McLeod; Stefanie Ferreri
Pharmacogenomics in a community pharmacy: ACT now.
Journal of the American Pharmacists Association : JAPhA. 2011;51(2):189-193.1 -
52.
2011Benjamin R. Tan; Fabienne Thomas; Robert J. Myerson; Barbara Zehnbauer; Kathryn Trinkaus; Robert S. Malyapa; Matthew G. Mutch; Elliot E. Abbey; Amer Alyasiry; James W. Fleshman; et al.
Journal of Clinical Oncology. 2011;29(7):875-883.8 -
53.
2011Soo-Youn Lee; Howard L McLeod
Pharmacogenetic tests in cancer chemotherapy: What physicians should know for clinical application
Journal of Pathology. 2011;223(1):15-27.13 -
54.
2011Venita Gresham Watson; Alison Motsinger-Reif; Nicholas E. Hardison; Eric J. Peters; Tammy M. Havener; Lorraine Everitt; James Todd Auman; Daniel L. Comins; Howard L. McLeod
PLoS ONE. 2011;6(5).4 -
55.
2011H.L. McLeod; G. Tortora; L.H. Rowett; J.B. Vermorken
Found in translation: Annals of Oncology and translational research
Annals of Oncology. 2011;22(8):1698-1699.1 -
56.
2011Chad Brown; Tammy M. Havener; Lorraine Everitt; Howard McLeod; Alison A. Motsinger-Reif
A comparison of association methods for cytotoxicity mapping in pharmacogenomics
Frontiers in Genetics. 2011;2(DEC).2 -
57.
2010Amelia Warner; Anita Nelsen; Anahita Bhathena; Kevin Fitzgerald; Sandra Gilardi; Ellen Kelso; Bartha Knoppers; Howard L. McLeod; Robert Nelson; Yoshi Uyama; et al.
Enabling pharmacogenomic clinical trials through sampling
Pharmacogenomics. 2010;11(12):1649-1654.3 -
58.
2010Roshawn G. Watson; Filipe Muhale; Leigh B. Thorne; Jinsheng Yu; Bert H. O'Neil; Janelle M. Hoskins; Michael O. Meyers; Allison M. Deal; Joseph G. Ibrahim; Michael L. Hudson; et al.
European Journal of Cancer. 2010;46(18):3358-3364.2 -
59.
2010Alessandro Schipani; Marco Siccardi; Antonio D'Avolio; Lorena Baietto; Marco Simiele; Stefano Bonora; Sonia Rodríguez Novoa; Lorena Cuenca; Vincent Soriano; Nitipatana Chierakul; et al.
Antimicrobial Agents and Chemotherapy. 2010;54(12):5242-5250.8 -
60.
2010Fabienne Thomas; Janelle M. Hoskins; Anne Dvorak; Benjamin R. Tan; Howard L. McLeod
Pharmacogenomics. 2010;11(12):1751-1756.3 -
61.
2010Andrew N. Freedman; Leah B. Sansbury; William D. Figg; Arnold L. Potosky; Sheila R. Weiss Smith; Muin J. Khoury; Stefanie A. Nelson; Richard M. Weinshilboum; Mark J. Ratain; Howard L. McLeod; et al.
Journal of the National Cancer Institute. 2010;102(22):1698-1705.19 -
62.
2010Helga Blasius; Claudia Bruhn; Christoph Gradmann; Johannes-Peter Stasch; Bernhard Keppler; Heyo K. Kroemer; Edzard Ernst; Howard L. McLeod; Jochen Seufert; Rudi Balling
Personalized therapeutics - Dream or reality?
Deutsche Apotheker Zeitung. 2010;150(42):68-82.0 -
63.
2010Gianluigi Zaza; Meyling Cheok; Natalia Krynetskaia; Caroline Thorn; Gabriele Stocco; Joan M. Hebert; Howard McLeod; Richard M. Weinshilboum; Mary V. Relling; et al.
Pharmacogenetics and Genomics. 2010;20(9):573-574.7 -
64.
2010Howard L. McLeod; Daniel J. Sargent; Sharon Marsh; Erin M. Green; Cristi R. King; Charles S. Fuchs; Ramesh K. Ramanathan; Stephen K. Williamson; Brian P. Findlay; Stephen N. Thibodeau; et al.
Journal of Clinical Oncology. 2010;28(20):3227-3233.43 -
65.
2010Howard L. McLeod
Using patient DNA to optimize therapy in heart failure patients: A move toward perfection
Heart Failure Reviews. 2010;15(3):183-185.2 -
66.
2010Mary W. Roederer; Howard L. McLeod
Applying the genome to national drug formulary policy in the developing world
Pharmacogenomics. 2010;11(5):633-636.6 -
67.
2010Prabha Ranganathan; Howard McLeod
Race and methotrexate pharmacogenetics in rheumatoid arthritis
Journal of Rheumatology. 2010;37(5):1064.0 -
68.
2010Michael L. Maitland; Xing Jian Lou; Jacqueline Ramirez; Apurva A. Desai; Dorit S. Berlin; Howard L. McLeod; Ralph R. Weichselbaum; Mark J. Ratain; Russ B. Altman; et al.
Vascular endothelial growth factor pathway
Pharmacogenetics and Genomics. 2010;20(5):346-349.3 -
69.
2010D. Voora; D.C. Koboldt; C.R. King; P.A. Lenzini; C.S. Eby; R. Porche-Sorbet; E. Deych; M. Crankshaw; P.E. Milligan; H.L. McLeod; et al.
Clinical Pharmacology and Therapeutics. 2010;87(4):445-451.23 -
70.
2010Derek Van Booven; Sharon Marsh; Howard McLeod; Michelle Whirl Carrillo; Katrin Sangkuhl; Teri E. Klein; Russ B. Altman
Pharmacogenetics and Genomics. 2010;20(4):277-281.11 -
71.
2010Patricia A. Deverka; John Vernon; Howard L. McLeod
Economic opportunities and challenges for pharmacogenomics
Annual Review of Pharmacology and Toxicology. 2010;50:423-437.17 -
72.
2010J.T. Auman; H.L. McLeod
Now's the time to find biomarkers on purpose
Annals of Oncology. 2010;21(2):193-194.2 -
73.
2010James Todd Auman; Howard L. McLeod
Colorectal cancer cell lines lack the molecular heterogeneity of clinical colorectal tumors
Clinical Colorectal Cancer. 2010;9(1):40-47.3 -
74.
2010Sharon Cresci; Janice M. Huss; Amber L. Beitelshees; Philip G. Jones; Matt R. Minton; Gerald W. Dorn II; Daniel P. Kelly; John A. Spertus; Howard L. McLeod
PLoS ONE. 2010;5(9):1-9.1 -
75.
2010Amber L. Beitelshees; Julie A. Johnson; Megan L. Hames; Yan Gong; Rhonda M. Cooper-Dehoff; Jun Wu; Sharon Cresci; Cynthia X. Ma; Carl J. Pepine; Michael A. Province; et al.
PLoS ONE. 2010;5(12):1-6.0 -
76.
2010Richard M Goldberg; Daniel J Sargent; Howard McLeod
Transactions of the American Clinical and Climatological Association. 2010;121:21-32; discussion 32-33.1 -
77.
2010Sharon Cresci; Janice M Huss; Amber L Beitelshees; Philip G Jones; Matt R Minton; Gerald W Dorn; Daniel P Kelly; John A Spertus; Howard L McLeod
PloS one. 2010;5(9):e12584.5 -
78.
2010Amber L Beitelshees; Julie A Johnson; Megan L Hames; Yan Gong; Rhonda M Cooper-Dehoff; Jun Wu; Sharon Cresci; Cynthia X Ma; Carl J Pepine; Michael A Province; et al.
PloS one. 2010;5(12):e15180.1 -
79.
2010N.S. Ferder; C.S. Eby; E. Deych; J.K. HARRIS; P.M. Ridker; P.E. Milligan; S.Z. Goldhaber; C.R. King; T. Giri; H.L. Mcleod; et al.
Journal of Thrombosis and Haemostasis. 2010;8(1):95-100.31 -
80.
2010Tejinder K. Rakhra-Burris; J. Todd Auman; Patricia Deverka; Lynn G. Dressler; James P. Evans; Richard M. Goldberg; Tammy M. Havener; Janelle M. Hoskins; Daniel E. Jonas; Kevin M. Long; et al.
Pharmacogenomics. 2010;11(1):13-21.1 -
81.
2009Marleen Welsh; Lara Mangravite; Marisa Wong Medina; Kelan Tantisira; Wei Zhang; R. Stephanie Huang; Howard McLeod; M. Eileen Dolan
Pharmacogenomic discovery using cell-based models
Pharmacological Reviews. 2009;61(4):413-429.43 -
82.
2009Connie Oshiro; Sharon Marsh; Howard McLeod; Michelle Whirl Carrillo; Teri Klein; Russ Altman
Pharmacogenetics and Genomics. 2009;19(12):979-983.6 -
83.
2009J.L. Yen-Revollo; D.J. Van Booven; E.J. Peters; J.M. Hoskins; R.M. Engen; H.D. Kannall; D. Ofori-Adjei; H.L. McLeod; S. Marsh
Influence of ethnicity on pharmacogenetic variation in the ghanaian population
Pharmacogenomics Journal. 2009;9(6):373-379.3 -
84.
2009Soo-Chin Lee; Xin Xu; Wee-Joo Chng; Mark Watson; Yi-Wan Lim; Chiung-Ing Wong; Philip Iau; Norita Sukri; Siew-Eng Lim; Hui-Ling Yap; et al.
Pharmacogenetics and Genomics. 2009;19(11):833-842.5 -
85.
2009Joseph S. Rossi; Howard L. McLeod
The Pharmacogenetics of Statin Therapy. When the Body Aches, the Mind Will Follow
Journal of the American College of Cardiology. 2009;54(17):1617-1618.4 -
86.
2009Daniel L. Hertz; Howard L. McLeod; Janelle M. Hoskins
Pharmacogenetics of breast cancer therapies
Breast. 2009;18(SUPPL.3):S59-S63.7 -
87.
2009Hanna K. Sanoff; Daniel J. Sargent; Erin M. Green; Howard L. McLeod; Richard M. Goldberg
Journal of Clinical Oncology. 2009;27(25):4109-4115.20 -
88.
2009Janelle M. Hoskins; Lisa A. Carey; Howard L. McLeod
CYP2D6 and tamoxifen: DNA matters in breast cancer
Nature Reviews Cancer. 2009;9(8):576-586.106 -
89.
2009David R. Gandara; Tomoya Kawaguchi; John Crowley; James Moon; Kiyoyuki Furuse; Masaaki Kawahara; Satoshi Teramukai; Yuichiro Ohe; Kaoru Kubota; Stephen K. Williamson; et al.
Journal of Clinical Oncology. 2009;27(21):3540-3546.70 -
90.
2009Daniel E. Jonas; Howard L. McLeod
Genetic and clinical factors relating to warfarin dosing
Trends in Pharmacological Sciences. 2009;30(7):375-386.34 -
91.
2009Sharon Marsh; Howard McLeod; Eileen Dolan; Sunita J. Shukla; Cara A. Rabik; Li Gong; Tina Hernandez-Boussard; Xing Jian Lou; Teri E. Klein; Russ B. Altman
Pharmacogenetics and Genomics. 2009;19(7):563-564.6 -
92.
2009Jun Yang; Alessia Bogni; Erin G. Schuetz; Mark Ratain; M. Eileen Dolan; Howard McLeod; Li Gong; Caroline Thorn; Mary V. Relling; Teri E. Klein; et al.
Pharmacogenetics and Genomics. 2009;19(7):552-553.5 -
93.
2009Jeffrey G. Kuremsky; Joel E. Tepper; Howard L. McLeod
Biomarkers for Response to Neoadjuvant Chemoradiation for Rectal Cancer
International Journal of Radiation Oncology Biology Physics. 2009;74(3):673-688.81 -
94.
2009Janelle M. Hoskins; Gary L. Rosner; Mark J. Ratain; Howard L. McLeod; Federico Innocenti
Pharmacogenomics. 2009;10(7):1139-1146.5 -
95.
2009Janelle M. Hoskins; Mary W. Roederer; Howard L. McLeod
Nevirapine hypersensitivity reaction: Will the real HLA please stand up?
Current Opinion in Molecular Therapeutics. 2009;11(3):226-230.2 -
96.
2009Venita Gresham; Howard L. McLeod
Genomics: Applications in mechanism elucidation
Advanced Drug Delivery Reviews. 2009;61(5):369-374.4 -
97.
2009Janelle M. Hoskins; Howard L. McLeod
UGT1A and irinotecan toxicity: Keeping it in the family
Journal of Clinical Oncology. 2009;27(15):2419-2421.5 -
98.
2009Eric J. Peters; Aldi T. Kraja; Shiow J. Lin; Jane L. Yen-Revollo; Sharon Marsh; Michael A. Province; Howard L. McLeod
Association of thymidylate synthase variants with 5-fluorouracil cytotoxicity
Pharmacogenetics and Genomics. 2009;19(5):399-401.8 -
99.
2009Michael R. Langley; Jessica K. Booker; James P. Evans; Howard L. McLeod; Karen E. Weck
Journal of Molecular Diagnostics. 2009;11(3):216-225.28 -
100.
2009Louise Wideroff; Kathryn A. Phillips; Gurvaneet Randhawa; Anita Ambs; Katrina Armstrong; Charles L. Bennett; Martin L. Brown; Molla S. Donaldson; Michele Follen; Sue J. Goldie; et al.
A health services research agenda for cellular, molecular and genomic technologies in cancer care
Public Health Genomics. 2009;12(4):233-244.8 -
101.
2009Soo-Chin Lee; Xin Xu; Yi-Wan Lim; Philip Lau; Norita Sukri; Siew-Eng Lim; Hui Ling Yap; Wee-Lee Yeo; Patrick Tan; Sing-Huang Tan; et al.
Chemotherapy-induced tumor gene expression changes in human breast cancers
Pharmacogenetics and Genomics. 2009;19(3):181-192.8 -
102.
2009Christine M. Walko; Howard McLeod
Pharmacogenomic progress in individualized dosing of key drugs for cancer patients
Nature Reviews Clinical Oncology. 2009;6(3):153-162.7 -
103.
2009Sarah R. McWhinney; Howard L. McLeod
Using germline genotype in cancer pharmacogenetic studies
Pharmacogenomics. 2009;10(3):489-493.12 -
104.
2009James J. Crowley; Patrick F. Dullivan; Howard L. McLeod
Pharmacogenomic genome-wide association studies: Lessons learned thus far
Pharmacogenomics. 2009;10(2):161-163.22 -
105.
2009David Gurwitz; Howard L. McLeod
Genome-wide association studies: Powerful tools for improving drug safety and efficacy
Pharmacogenomics. 2009;10(2):157-159.13 -
106.
2009Richard M. Goldberg; Daniel J. Sargent; Roscoe F. Morton; Erin Green; Hanna K. Sanoff; Howard McLeod; Jan Buckner
NCCTG study N9741: Leveraging learning from an NCI cooperative group phase III trial
Oncologist. 2009;14(10):970-978.4 -
107.
2009Elisabete Oliveira; Rui Pereira; António Amorim; Howard McLeod; Maria João Prata
Patterns of pharmacogenetic diversity in African populations: Role of ancient and recent history
Pharmacogenomics. 2009;10(9):1413-1422.1 -
108.
2009Kyle J. Ellis; George A. Stouffer; Howard L. McLeod; Craig R. Lee
Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations
Pharmacogenomics. 2009;10(11):1799-1817.32 -
109.
2009Christine M. Walko; Howard McLeod
Pharmacogenomic progress in individualized dosing of key drugs for cancer patients
Nature Clinical Practice Oncology. 2009;6(3):153-162.9 -
110.
2009Shriya Bhushan; Howard McLeod; Christine M. Walko
Clinical Colorectal Cancer. 2009;8(1):15-21.8 -
111.
2009Sarah R. McWhinney; Richard M. Goldberg; Howard L. McLeod
Platinum neurotoxicity pharmacogenetics
Molecular Cancer Therapeutics. 2009;8(1):10-16.74 -
112.
2008J.T. Auman; H.L. McLeod
Applications of genomic tools to colorectal cancer therapeutics
Current Opinion in Molecular Therapeutics. 2008;10(6):548-554.1 -
113.
2008Hanna K. Sanoff; Howard L. McLeod
Predictive Factors for Response and Toxicity in Chemotherapy: Pharmacogenomics
Seminars in Colon and Rectal Surgery. 2008;19(4):226-230.1 -
114.
2008Lang Li; Menggang Yu; Robarge D. Jason; Changyu Shen; Faouzi Azzouz; Howard L. McLeod; Silvana Borges-Gonzales; Anne Nguyen; Todd Skaar; Zeruesenay Desta; et al.
A mixture model approach in gene-gene and gene-environmental interactions for binary phenotypes
Journal of Biopharmaceutical Statistics. 2008;18(6):1150-1177.1 -
115.
2008Eric J Peters; Howard L McLeod
Editorial: Ability of whole-genome SNP arrays to capture 'must have pharmacogenomic variants
Pharmacogenomics. 2008;9(11):1573-1577.10 -
116.
2008Jane L. Yen-Revollo; J Todd Auman; Howard L. McLeod
Race does not explain genetic heterogeneity in pharmacogenomic pathways
Pharmacogenomics. 2008;9(11):1639-1645.8 -
117.
2008Cindy H. Chau; Olivier Rixe; Howard McLeod; William D. Figg
Validation of analytic methods for biomarkers used in drug development
Clinical Cancer Research. 2008;14(19):5967-5976.46 -
118.
2008Tatsuki Fukami; Miki Nakajima; Taiga Maruichi; Shiori Takahashi; Masataka Takamiya; Yasuhiro Aoki; Howard L. McLeod; Tsuyoshi Yokoi
Structure and characterization of human carboxylesterase 1A1,1A2, and 1A3 genes
Pharmacogenetics and Genomics. 2008;18(10):911-920.18 -
119.
2008Jinsheng Yu; Robert R. Freimuth; Robert Culverhouse; Sharon Marsh; Mark A. Watson; Howard L. McLeod
DNA methylotype analysis in colorectal cancer
Oncology Reports. 2008;20(4):921-927.2 -
120.
2008Sharon E. Johnatty; Jonathan Beesley; Jim Paul; Sian Fereday; Amanda B. Spurdle; Penelope M.webb; Karen Byth; Sharon Marsh; Howard McLeod; Paul R. Harnett; et al.
Clinical Cancer Research. 2008;14(17):5594-5601.35 -
121.
2008B.F. Gage; C. Eby; J.A. Johnson; E. Deych; M.J. Rieder; P.M. Ridker; P.E. Milligan; G. Grice; P. Lenzini; et al.
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
Clinical Pharmacology and Therapeutics. 2008;84(3):326-331.238 -
122.
2008B.F. Gage; C. Eby; J.A. Johnson; E. Deych; M.J. Rieder; P.M. Ridker; P.E. Milligan; G. Grice; P. Lenzini; et al.
Clinical Pharmacology and Therapeutics. 2008;84(3):430.0 -
123.
2008James Todd Auman; Robert Church; Soo-Youn Lee; Mark A. Watson; James W. Fleshman; Howard L. Mcleod
European Journal of Cancer. 2008;44(12):1754-1760.11 -
124.
2008P.A. Deverka; H.L. McLeod
Harnessing economic drivers for successful clinical implementation of pharmacogenetic testing
Clinical Pharmacology and Therapeutics. 2008;84(2):191-193.13 -
125.
2008William D. Figg; Cindy H. Chau; Richard Okita; Peter Preusch; Timothy S. Tracy; Howard McLeod; Michael Reed; John Pieper; Daren Knoell; Ken Miller; et al.
Pharmacotherapy. 2008;28(7):821-833.5 -
126.
20080 -
127.
2008Scott T. Weiss; Howard L. McLeod; David A. Flockhart; M. Eileen Dolan; Neal L. Benowitz; Julie A. Johnson; Mark J. Ratain; Kathleen M. Giacomini
Creating and evaluating genetic tests predictive of drug response
Nature Reviews Drug Discovery. 2008;7(7):568-574.25 -
128.
2008D.N. Hayes; H.L. McLeod
Annals of Oncology. 2008;19(6):1036-1037.1 -
129.
2008J.J. Crowley; P.F. Sullivan; H.L. McLeod
Untapped resources for pharmacogenomic discovery in psychiatry
Current Opinion in Molecular Therapeutics. 2008;10(3):205-206.0 -
130.
2008Sripathi M. Sureban; Randal May; Robert J. George; Brian K. Dieckgraefe; Howard L. McLeod; Satish Ramalingam; Kumar S. Bishnupuri; Gopalan Natarajan; Shrikant Anant; Courtney W. Houchen
Knockdown of RNA Binding Protein Musashi-1 Leads to Tumor Regression In Vivo
Gastroenterology. 2008;134(5):1448-1458.e2.54 -
131.
2008J. Todd Auman; Howard L. McLeod
Drug Metabolism Reviews. 2008;40(2):303-315.8 -
132.
2008Prabha Ranganathan; Robert Culverhouse; Sharon Marsh; Ami Mody; Tiffany J. Scott-Horton; Richard Brasington; Amy Joseph; Virginia Reddy; Seth Eisen; et al.
Journal of Rheumatology. 2008;35(4):572-579.63 -
133.
2008Patrick Cahan; Laura E. Godfrey; Peggy S. Eis; Todd A. Richmond; Rebecca R. Selzer; Michael Brent; Howard L. Mcleod; Timothy J. Ley; Timothy A. Graubert
Nucleic Acids Research. 2008;36(7).18 -
134.
2008Janelle M. Hoskins; Eugenio Marcuello; Albert Altes; Sharon Marsh; Taylor Maxwell; Derek J. Van Booven; Laia Paré; Robert Culverhouse; Howard L. McLeod; Montserrat Baiget
Irinotecan pharmacogenetics: Influence of pharmacodynamic genes
Clinical Cancer Research. 2008;14(6):1788-1796.36 -
135.
2008Janelle M. Hoskins; Howard L. McLeod
Journal of the National Cancer Institute. 2008;100(3):225.0 -
136.
2008B.R. Tan; W.S. Brenner; J. Picus; S. Marsh; F. Gao; C. Fournier; P.M. Fracasso; J. James; J.L. Yen-Revollo; H.L. McLeod
Annals of Oncology. 2008;19(10):1742-1748.4 -
137.
2008Jinsheng Yu; Ryan Miller; Wanghai Zhang; Mala Sharma; Vicky Holtschlag; Mark A. Watson; Howard L. McLeod
Pharmacogenomics. 2008;9(10):1459-1466.6 -
138.
2008P. Brent Ferrell Jr.; Howard L. McLeod
Pharmacogenomics. 2008;9(10):1543-1546.65 -
139.
2008Sharon Cresci; Philip G. Jones; Carmen C. Sucharov; Sharon Marsh; David E. Lanfear; Adam Garsa; Michael Courtois; Carla J. Weinheimer; Jun Wu; Michael A. Province; et al.
Pharmacogenomics. 2008;9(10):1403-1417.4 -
140.
2008Janna E. Hutz; Aldi T. Kraja; Howard L. McLeod; Michael A. Province
CANDID: A flexible method for prioritizing candidate genes for complex human traits
Genetic Epidemiology. 2008;32(8):779-790.25 -
141.
2008Jane L. Yen-Revollo; Richard M. Goldberg; Howard L. McLeod
Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?
Clinical Cancer Research. 2008;14(1):8-13.29 -
142.
2008Christine M. Walko; Howard L. McLeod
Will we ever be ready for blood level-guided therapy?
Journal of Clinical Oncology. 2008;26(13):2078-2079.7 -
143.
2008Sharon Marsh; Jim Paul; Howard L. McLeod; Robert Brown
Journal of Clinical Oncology. 2008;26(10):1767-1768.0 -
144.
2008Jim Paul; Sharon Marsh; Howard L. McLeod; Robert Brown
Journal of Clinical Oncology. 2008;26(11):1904-1905.0 -
145.
2007Chris Papageorgio; Rainer Brachmann; Jue Zeng; Robert Culverhouse; Wanghai Zhang; Howard McLeod
MAGED2: A novel p53-dissociator
International Journal of Oncology. 2007;31(5):1205-1211.4 -
146.
2007David E. Lanfear; Howard L. McLeod
Pharmacogenetics: Using DNA to optimize drug therapy
American Family Physician. 2007;76(8):1179-1182.21 -
147.
2007Sharon Marsh; Jim Paul; Cristi R. King; Gillian Gifford; Howard L. McLeod; Robert Brown
Journal of Clinical Oncology. 2007;25(29):4528-4535.113 -
148.
2007Aminah Jatoi; James A. Martenson; Nathan R. Foster; Howard L. McLeod; Bradley S. Lair; Frank Nichols; Loren K. Tschetter; Dennis F. Moore Jr.; Tom R. Fitch; et al.
American Journal of Clinical Oncology: Cancer Clinical Trials. 2007;30(5):507-513.9 -
149.
2007S. Marsh; G. Somlo; X. Li; P. Frankel; C.R. King; W.D. Shannon; H.L. McLeod; T.W. Synold
Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer
Pharmacogenomics Journal. 2007;7(5):362-365.52 -
150.
2007Janelle M. Hoskins; Richard M. Goldberg; Pingping Qu; Joseph G. Ibrahim; Howard L. McLeod
UGT1A1*28 genotype and irinotecan-induced neutropenia: Dose matters
Journal of the National Cancer Institute. 2007;99(17):1290-1295.173 -
151.
2007David E. Lanfear; Philip G. Jones; Sharon Marsh; Sharon Cresci; John A. Spertus; Howard L. McLeod
Connexin37 (GJA4) genotype predicts survival after an acute coronary syndrome
American Heart Journal. 2007;154(3):561-566.18 -
152.
2007E. Oliveira; S. Marsh; D.J. van Booven; A. Amorim; M.J. Prata; H.L. McLeod
Pharmacogenetically relevant polymorphisms in Portugal
Pharmacogenomics. 2007;8(7):703-712.13 -
153.
2007Weiguang Wang; Howard L. McLeod; James Cassidy; Elaina S. R. Collie-Duguid
Cancer Chemotherapy and Pharmacology. 2007;59(6):839-845.15 -
154.
2007Cristi R. King; Ming Xiao; Jinsheng Yu; Matthew R. Minton; Nicholas J. Addleman; Derek J. Van Booven; Pui-Yan Kwok; Howard L. McLeod; Sharon Marsh
Identification of NR1I2 genetic variation using resequencing
European Journal of Clinical Pharmacology. 2007;63(6):547-554.13 -
155.
2007H.L. McLeod
Drug pathways: One gene is not enough
Current Opinion in Molecular Therapeutics. 2007;9(3):214-215.0 -
156.
2007Russ B. Altman; Neal Benowitz; David Gurwitz; Jeantine Lunshol; Mary Relling; Jatinder Lamba; Eric Wieben; Sean Mooney; Kathleen Giacomini; Scott Weiss; et al.
Genetic nondiscrimination legislation: A critical prerequisite for pharmacogenomics data sharing
Pharmacogenomics. 2007;8(5):519.6 -
157.
2007W.T. Lim; W.H. Zhang; C.R. Miller; J.W. Watters; F. Gao; A. Viswanathan; R. Govindan; H.L. McLeod
Oncology reports. 2007;17(4):853-857.38 -
158.
2007David Gurwitz; Howard L. McLeod
Primum non nocere: Adverse drug events must be taken seriously
Pharmacogenomics. 2007;8(4):311-314.5 -
159.
2007Jane L. Yen; Howard L. McLeod
Should DPD analysis be required prior to prescribing fluoropyrimidines?
European Journal of Cancer. 2007;43(6):1011-1016.58 -
160.
2007Tatsuki Fukami; Miki Nakajima; Hiroyuki Yamanaka; Yasunari Fukushima; Howard L. McLeod; Tsuyoshi Yokoi
A novel duplication type of CYP2A6 gene in African-American population
Drug Metabolism and Disposition. 2007;35(4):515-520.24 -
161.
2007K.M. Giacomini; C.M. Brett; R.B. Altman; N.L. Benowitz; M.E. Dolan; D.A. Flockhart; J.A. Johnson; D.F. Hayes; T. Klein; R.M. Krauss; et al.
The Pharmacogenetics Research Network: From SNP discovery to clinical drug response
Clinical Pharmacology and Therapeutics. 2007;81(3):328-345.98 -
162.
2007Sharon Marsh; Howard L. McLeod
Pharmacogenetics and oncology treatment for breast cancer
Expert Opinion on Pharmacotherapy. 2007;8(2):119-127.23 -
163.
2007David E. Lanfear; Joshua M. Stolker; Sharon Marsh; Michael W. Rich; Howard L. McLeod
Genetic variation in the B-type natiuretic peptide pathway affects BNP levels
Cardiovascular Drugs and Therapy. 2007;21(1):55-62.20 -
164.
2007Timothy A Graubert; Patrick Cahan; Deepa Edwin; Rebecca R Selzer; Todd A Richmond; Peggy S Eis; William D Shannon; Xia Li; Howard L McLeod; James M Cheverud; et al.
A high-resolution map of segmental DNA copy number variation in the mouse genome.
PLoS genetics. 2007;3(1):e3.29 -
165.
2007C. Ryan Miller; Howard L. McLeod
Pharmacogenomics of cancer chemotheraphy-induced toxicity
Journal of Supportive Oncology. 2007;5(1):9-14.15 -
166.
2007N.F. Smith; S. Marsh; T.J. Scott-Horton; A. Hamada; S. Mielke; K. Mross; W.D. Figg; J. Verweij; H.L. McLeod; A. Sparreboom
Clinical Pharmacology and Therapeutics. 2007;81(1):76-82.68 -
167.
2007F.A. De Jong; T.J. Scott-Horton; D.L. Kroetz; H.L. McLeod; L.E. Friberg; R.H. Mathijssen; J. Verweij; S. Marsh; A. Sparreboom
Irinotecan-induced diarrhea: Functional significance of the polymorphic ABCC2 transporter protein
Clinical Pharmacology and Therapeutics. 2007;81(1):42-49.84 -
168.
2007Howard McLeod
Graying anatomy? Toward molecular tumor characterization
Pharmacogenomics. 2007;8(1):15-16.1 -
169.
2007Timothy A. Graubert; Patrick Cahan; Deepa Edwin; Rebecca R. Selzer; Todd A. Richmond; Peggy S. Eis; William D. Shannon; Xia Li; Howard L. McLeod; James M. Cheverud; et al.
A high-resolution map of segmental DNA copy number variation in the mouse genome
PLoS Genetics. 2007;3(1):0021-0029.72 -
170.
20060 -
171.
2006R.M. Engen; S. Marsh; D.J. Van Booven; H.L. McLeod
Ethnic differences in pharmacogenetically relevant genes
Current Drug Targets. 2006;7(12):1641-1648.23 -
172.
2006David E. Lanfear; Joshua M. Stolker; Sharon Marsh; Michael W. Rich; Howard L. McLeod
Therapy. 2006;3(6):765-771.2 -
173.
2006T. Fukami; M. Nakajima; H. Sakai; H.L. McLeod; T. Yokoi
CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele
Pharmacogenomics Journal. 2006;6(6):401-412.13 -
174.
2006David E. Lanfear; John A. Spertus; Howard L. McLeod
β2-adrenergic receptor genotype predicts survival: Implications and future directions
Journal of Cardiovascular Nursing. 2006;21(6):474-477.3 -
175.
2006Christine B. Ambrosone; Timothy R. Rebbeck; Gareth J. Morgan; Kathy S. Albain; Eugenia E. Calle; William E. Evans; Daniel F. Hayes; Lawrence H. Kushi; Howard L. McLeod; et al.
Cancer Epidemiology Biomarkers and Prevention. 2006;15(11):2042-2046.9 -
176.
2006Giancarlo A. Pillot; William L. Read; Kristin L. Hennenfent; Sharon Marsh; Feng Gao; Avinash Viswanathan; Kristopher Cummings; Howard L. McLeod; Ramaswamy Govindan
Journal of Thoracic Oncology. 2006;1(9):972-978.21 -
177.
2006Noah M. Hahn; Sharon Marsh; William Fisher; Robert Langdon; Robin Zon; Mark Browning; Cynthia S. Johnson; Tiffany J. Scott-Horton; Lang Li; Howard L. McLeod; et al.
Clinical Cancer Research. 2006;12(20 PART 1):6094-6099.27 -
178.
2006Amber L. Beitelshees; Howard L. McLeod
Applying pharmacogenomics to enhance the use of biomarkers for drug effect and drug safety
Trends in Pharmacological Sciences. 2006;27(9):498-502.8 -
179.
2006Bert H. O'Neil; Howard L. McLeod
Thymidine phosphorylase and capecitabine: A predictive marker for therapy selection?
Journal of Clinical Oncology. 2006;24(25):4051-4053.3 -
180.
2006Jinsheng Yu; Mary A. Mallon; Wanghai Zhang; Robert R. Freimuth; Sharon Marsh; Mark A. Watson; Paul J. Goodfellow; Howard L. McLeod
DNA repair pathway profiling and microsatellite instability in colorectal cancer
Clinical Cancer Research. 2006;12(17):5104-5111.17 -
181.
2006Miki Nakajima; Tatsuki Fukami; Hiroyuki Yamanaka; Eriko Higashi; Haruko Sakai; Ryoko Yoshida; Jun-Tack Kwon; Howard L. McLeod; Tsuyoshi Yokoi
Clinical Pharmacology and Therapeutics. 2006;80(3):282-297.92 -
182.
2006William C. Zamboni; Ramesh K. Ramanathan; Howard L. McLeod; Sridhar Mani; Douglas M. Potter; Sandra Strychor; Lauren J. Maruca; Cristi R. King; Laura L. Jung; et al.
Investigational New Drugs. 2006;24(5):393-401.23 -
183.
2006Amber L. Beitelshees; Howard L. McLeod
Clopidogrel pharmacogenetics: Promising steps towards patient care?
Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26(8):1681-1683.15 -
184.
2006Eric Knoche; Howard L. McLeod; Timothy A. Graubert
Pharmacogenetics of alkylator-associated acute myeloid leukemia
Pharmacogenomics. 2006;7(5):719-729.6 -
185.
2006Sharon Marsh; Cristi R. King; Howard L. McLeod; Jim Paul; Gillian Gifford; Robert Brown
ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer [1]
Clinical Cancer Research. 2006;12(13):4127.14 -
186.
2006Jinsheng Yu; Howard L. McLeod
Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase deficiency [1]
Clinical Cancer Research. 2006;12(12):3864.13 -
187.
2006Mark J. Ratain; Antonius A. Miller; Howard L. McLeod; Alan P. Venook; Merrill J. Egorin; Richard L. Schilsky
Clinical Cancer Research. 2006;12(11 II):3612s-3616s.11 -
188.
2006Sharon Marsh; Derek J. Van Booven; Howard L. McLeod
Global pharmacogenetics: Giving the genome to the masses
Pharmacogenomics. 2006;7(4):625-631.18 -
189.
2006Jennifer E. Van Eyk; Lukas A. Huber; Lex M. Cowsert; Howard L. McLeod
Genomics, proteomics and pharmacogenetics - Experimental approaches
Current Opinion in Molecular Therapeutics. 2006;8(3):183-184.0 -
190.
2006W. Zhang; W.D. Shannon; J. Duncan; G.L. Scheffer; R.J. Scheper; H.L. McLeod
Expression of drug pathway proteins is independent of tumour type
Journal of Pathology. 2006;209(2):213-219.18 -
191.
2006Timothy S. Fenske; Christine McMahon; Deepa Edwin; Joseph C. Jarvis; James M. Cheverud; Matthew Minn; Vikram Mathews; Molly A. Bogue; Michael A. Province; Howard L. McLeod; et al.
Cancer Research. 2006;66(10):5029-5038.23 -
192.
2006Dan M. Roden; Russ B. Altman; Neal L. Benowitz; David A. Flockhart; Kathleen M. Giacomini; Julie A. Johnson; Ronald M. Krauss; Howard L. McLeod; Mark J. Ratain; Mary V. Relling; et al.
Pharmacogenomics: Challenges and opportunities
Annals of Internal Medicine. 2006;145(10):749-757.106 -
193.
2006Prabha Ranganathan; Howard L. McLeod
Methotrexate pharmacogenetics: The first step toward individualized therapy in rheumatoid arthritis
Arthritis and Rheumatism. 2006;54(5):1366-1377.58 -
194.
2006Daniel B. Brown; Shi-Rong Cai; Christopher E. Fundakowski; William C. Zamboni; Sandy Strychor; Howard L. McLeod
Pharmacokinetics after endovascular lung perfusion with cisplatin
Journal of Vascular and Interventional Radiology. 2006;17(5):883-888.5 -
195.
2006Sharon Marsh; Howard L McLeod
Pharmacogenomics: from bedside to clinical practice.
Human molecular genetics. 2006;15 Spec No 1:R89-93.51 -
196.
2006Howard L. McLeod
Individualizing cancer chemotherapy
Clinical Advances in Hematology and Oncology. 2006;4(4):259-261.2 -
197.
2006Patrick Cahan; Sharon Marsh; Howard L. McLeod
Systems pharmacogenomics in yeast
Pharmacogenomics. 2006;7(2):255-259.2 -
198.
2006J.M. Hoskins; H.L. McLeod
Cancer pharmacogenetics: The move from pharmacokinetics to pharmacodynamics
Current Pharmacogenomics. 2006;4(1):39-46.5 -
199.
2006Shi-Rong Cai; Guang Xu; Michelle Becker-Hapak; Margaret Ma; Steven F. Dowdy; Howard L. McLeod
The kinetics and tissue distribution of protein transduction in mice
European Journal of Pharmaceutical Sciences. 2006;27(4):311-319.64 -
200.
2006David E. Lanfear; John A. Spertus; Howard L. McLeod
Journal of the American Medical Association. 2006;295(7):757-758.0 -
201.
2006Gloria R. Grice; Terry L. Seaton; Abigail M. Woodland; Howard L. McLeod
Defining the opportunity for pharmacogenetic intervention in primary care
Pharmacogenomics. 2006;7(1):61-65.14 -
202.
2005Sharon Marsh; Mary Ann Mallon; Paul Goodfellow; Howard L. McLeod
Concordance of pharmacogenetic markers in germline and colorectal tumor DNA
Pharmacogenomics. 2005;6(8):873-877.30 -
203.
2005Robert R. Freimuth; Ming Xiao; Sharon Marsh; Matthew Minton; Nicholas Addleman; Derek J. Van Booven; Howard L. McLeod; Pui-Yan Kwok
Polymorphism discovery in 51 chemotherapy pathway genes
Human Molecular Genetics. 2005;14(23):3595-3603.14 -
204.
2005Lex M. Cowsert; Jennifer E. Van Eyk; Lukas A. Huber; Howard L. McLeod
Genomics, proteomics and pharmacogenetics - Therapeutic approaches
Current Opinion in Molecular Therapeutics. 2005;7(6):530-531.0 -
205.
2005Anja Henningsson; Sharon Marsh; Walter J. Loos; Mats O. Karlsson; Adam Garsa; Klaus Mross; Stephan Mielke; Lucia Viganò; Alberta Locatelli; et al.
Clinical Cancer Research. 2005;11(22):8097-8104.100 -
206.
2005Howard L. McLeod
Pharmacogenetic analysis of clinically relevant genetic polymorphisms
Clinical Infectious Diseases. 2005;41(SUPPL. 7):S449-S452.3 -
207.
2005Janelle M. Hoskins; Sharon Marsh; Howard L. McLeod; Harish V. Pai; Vijayalakshmi Ravindranath
Drug Metabolism and Disposition. 2005;33(10):1564-1566.3 -
208.
2005Jens M. Teodoridis; Jacqueline Hall; Sharon Marsh; Hilary D. Kannall; Catriona Smyth; Jorge Curto; Nadeem Siddiqui; Hani Gabra; Howard L. McLeod; Gordon Strathdee; et al.
CpG island methylation of DNA damage response genes in advanced ovarian cancer
Cancer Research. 2005;65(19):8961-8967.119 -
209.
2005Taylor J Maxwell; Margaret-Mary Ameyaw; Stuart Pritchard; Nadia Thornton; Gbolahan Folayan; Jessie Githang'a; Anne Indalo; Mohammed Tariq; Abeer Mobarek; David A Evans; et al.
Beta-2 adrenergic receptor genotypes and haplotypes in different ethnic groups.
International journal of molecular medicine. 2005;16(4):573-580.23 -
210.
2005David E. Lanfear; Philip G. Jones; Sharon Marsh; Sharon Cresci; Howard L. McLeod; John A. Spertus
Journal of the American Medical Association. 2005;294(12):1526-1533.109 -
211.
2005Daniel Morgensztern; Howard L. McLeod
PI3K/Akt/mTOR pathway as a target for cancer therapy
Anti-Cancer Drugs. 2005;16(8):797-803.111 -
212.
2005Tatsuki Fukami; Miki Nakajima; Eriko Higashi; Hiroyuki Yamanaka; Howard L. McLeod; Tsuyoshi Yokoi
Biochemical Pharmacology. 2005;70(5):801-808.29 -
213.
2005Tatsuki Fukami; Miki Nakajima; Eriko Higashi; Hiroyuki Yamanaka; Haruko Sakai; Howard L. McLeod; Tsuyoshi Yokoi
Drug Metabolism and Disposition. 2005;33(8):1202-1210.28 -
214.
200512 -
215.
2005P.M. Fracasso; K.A. Blum; M.K. Ma; B.R. Tan; L.P. Wright; S.A. Goodner; C.L. Fears; W. Hou; M.A. Arquette; J. Picus; et al.
Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar
British Journal of Cancer. 2005;93(1):46-53.17 -
216.
2005Lisa Bomgaars; Howard L. McLeod
Pharmacogenetics and pediatric cancer
Cancer Journal. 2005;11(4):314-323.3 -
217.
2005Shi-Rong Cai; Joel R Garbow; Robert Culverhouse; Robert D Church; Wanghai Zhang; William D Shannon; Howard L McLeod
A mouse model for developing treatment for secondary liver tumors.
International journal of oncology. 2005;27(1):113-120.11 -
218.
2005Elizabeth T. Wood; Daryn A. Stover; Christopher Ehret; Giovanni Destro-Bisol; Gabriella Spedini; Howard McLeod; Leslie Louie; Mike Bamshad; Beverly I. Strassmann; et al.
European Journal of Human Genetics. 2005;13(7):867-876.76 -
219.
2005Wanghai Zhang; John Hart; Howard L. McLeod; Hanlin L. Wang
American Journal of Clinical Pathology. 2005;124(1):11-19.18 -
220.
2005Deepak Voora; Howard L. McLeod; Charles Eby; Brian F. Gage
The pharmacogenetics of coumarin therapy
Pharmacogenomics. 2005;6(5):503-513.43 -
221.
2005Mark J. Rieder; Alexander P. Reiner; Brian F. Gage; Deborah A. Nickerson; Charles S. Eby; Howard L. McLeod; David K. Blough; Kenneth E. Thummel; David L. Veenstra; Allan E. Rettie
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose
New England Journal of Medicine. 2005;352(22):2285-2293.715 -
222.
2005Lex M. Cowsert; Jennifer E. van Eyk; Lukas A. Huber; Howard L. McLeod
Genomics, proteomics and pharmacogenetics - Experimental approaches
Current Opinion in Molecular Therapeutics. 2005;7(3):200-201.0 -
223.
2005Adam A. Garsa; Howard L. McLeod; Sharon Marsh
CYP3A4 and CYP3A5 genotyping by pyrosequencing
BMC Medical Genetics. 2005;6.36 -
224.
2005Rami G. Azrak; Jinsheng Yu; Lakshmi Pendyala; Patrick F. Smith; Shousong Cao; Xia Li; William D. Shannon; Farukh A. Durrani; Howard L. McLeod; Youcef M. Rustum
Molecular Cancer Therapeutics. 2005;4(5):843-854.8 -
225.
2005Deepak Voora; Charles Eby; Mark W. Linder; Paul E. Milligan; Bonny L. Bukaveckas; Howard L. McLeod; William Maloney; John Clohisy; R. Steven Burnett; Leonard Grosso; et al.
Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype
Thrombosis and Haemostasis. 2005;93(4):700-705.136 -
226.
2005Elizabeth A. Kidd; Jinsheng Yu; Xia Li; William D. Shannon; Mark A. Watson; Howard L. McLeod
Variance in the expression of 5-fluorouracil pathway genes in colorectal cancer
Clinical Cancer Research. 2005;11(7):2612-2619.37 -
227.
2005Charles A. Fox; Lisa M. Sapinoso; Hong Zhang; Wanghai Zhang; Howard L. McLeod; Gina R. Petroni; Tarun Mullick; Christopher A. Moskaluk; Henry F. Frierson; Garret M. Hampton; et al.
Altered expression of TFF-1 and CES-2 in Barrett's esophagus and associated adenocarcinomas
Neoplasia. 2005;7(4):407-416.16 -
228.
2005Richard A. Walgren; Howard L. McLeod
Small inhibitory RNA - A tool for credentialing candidate genes
Pharmacogenomics. 2005;6(3):281-292.1 -
229.
2005Jinsheng Yu; William D. Shannon; Mark A. Watson; Howard L. McLeod
Gene expression profiling of the irinotecan pathway in colorectal cancer
Clinical Cancer Research. 2005;11(5):2053-2062.33 -
230.
2005Samantha L. Hider; Patrick Hoggard; Saye Khoo; David Back; Ian N. Bruce; Prabha Ranganathan; Howard L. McLeod; Joel M. Kremer
Arthritis and Rheumatism. 2005;52(2):670-672.6 -
231.
2005Benjamin R. Tan; Howard L. McLeod
Pharmacogenetic influences on treatment response and toxicity in colorectal cancer
Seminars in Oncology. 2005;32(1 SPEC. ISS.):113-119.16 -
232.
2005Prabha Ranganathan; Howard L McLeod
Methotrexate and long-term treatment of rheumatic disease: comment on the article by Kremer.
Arthritis and rheumatism. 2005;52(2):670-671; author reply 672.1 -
233.
2005S.C. Glasgow; J. Yu; L.P. Carvalho; W.D. Shannon; J.W. Fleshman; H.L. McLeod
Unfavourable expression of pharmacologic markers in mucinous colorectal cancer
British Journal of Cancer. 2005;92(2):259-264.21 -
234.
2005C.R. King; J. Yu; R.R. Freimuth; H.L. McLeod; S. Marsh
Interethnic variability of ERCC2 polymorphisms
Pharmacogenomics Journal. 2005;5(1):54-59.15 -
235.
2005Robert R. Freimuth; Gary D. Stormo; Howard L. McLeod
PolyMAPr: Programs for polymorphism database mining, annotation, and functional analysis
Human Mutation. 2005;25(2):110-117.27 -
236.
2005Melissa A. Meucci; Sharon Marsh; James W. Watters; Howard L. McLeod
Pharmacogenomics. 2005;6(1):59-63.10 -
237.
2005Shufeng Zhou; Sui Yung Chan; Boon Cher Goh; Eli Chan; Wei Duan; Min Huang; Howard L. McLeod
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs
Clinical Pharmacokinetics. 2005;44(3):279-304.213 -
238.
2005Sharon Marsh; Cristi R King; Adam A Garsa; Howard L McLeod
Pyrosequencing of clinically relevant polymorphisms.
Methods in molecular biology (Clifton, N.J.). 2005;311:97-114.51 -
239.
2005Richard A. Walgren; Melissa A. Meucci; Howard L. McLeod
Pharmacogenomic discovery approaches: Will the real genes please stand up?
Journal of Clinical Oncology. 2005;23(29):7342-7349.25 -
240.
2004Tatsuki Fukami; Miki Nakajima; Ryoko Yoshida; Yuki Tsuchiya; Yuto Fujiki; Miki Katoh; Howard L. McLeod; Tsuyoshi Yokoi
Clinical Pharmacology and Therapeutics. 2004;76(6):519-527.42 -
241.
2004Ramaswamy Govindan; Howard McLeod; Prasad Mantravadi; Naomi Fineberg; Paul Helft; Kenneth Kesler; Nasser Hanna; Cindy Stoner; Rafat Ansari; et al.
Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results.
Oncology (Williston Park, N.Y.). 2004;18(14 Suppl 14):18-21.26 -
242.
2004William Read; Howard McLeod; Ramaswamy Govindan
Irinotecan and carboplatin in metastatic or recurrent NSCLC: an update.
Oncology (Williston Park, N.Y.). 2004;18(14 Suppl 14):15-17.0 -
243.
2004James W. Watters; Howard L. McLeod
Candidate gene selection in pharmacogenomics: Biology leads the way
Pharmacogenomics. 2004;5(8):1019-1022.0 -
244.
2004Patrick H. Rooney; Attasit Boonsong; Morag C.E. McFadyen; Howard L. McLeod; James Cassidy; Stephanie Curran; Graeme I. Murray
The candidate oncogene ZNF217 is frequently amplified in colon cancer
Journal of Pathology. 2004;204(3):282-288.30 -
245.
2004Sharon Marsh; Cristi R. King; Ranjeet Ahluwalia; Howard L. McLeod
Distribution of ITPA P32T alleles in multiple world populations
Journal of Human Genetics. 2004;49(10):579-581.38 -
246.
2004Sharon Marsh; Ming Xiao; Jinsheng Yu; Ranjeet Ahluwalia; Matthew Minton; Robert R. Freimuth; Pui-Yan Kwok; Howard L. McLeod
Pharmacogenomic assessment of carboxylesterases 1 and 2
Genomics. 2004;84(4):661-668.64 -
247.
2004David I. Min; Vicki L. Ellingrod; Sharon Marsh; Howard McLeod
CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects
Therapeutic Drug Monitoring. 2004;26(5):524-528.48 -
248.
2004Sharon Marsh; Howard L. McLeod
Pharmacogenetics of irinotecan toxicity
Pharmacogenomics. 2004;5(7):835-843.60 -
249.
2004R.D. Church; J. Yu; J.W. Fleshman; W.D. Shannon; R. Govindan; H.L. McLeod
RNA profiling of cyclooxygenases 1 and 2 in colorectal cancer
British Journal of Cancer. 2004;91(6):1015-1018.4 -
250.
2004Floris A. De Jong; Sharon Marsh; Ron H. J. Mathijssen; Cristi King; Jaap Verweij; Alex Sparreboom; Howard L. McLeod
Clinical Cancer Research. 2004;10(17):5889-5894.123 -
251.
2004Alasdair Breckenridge; Klaus Lindpaintner; Peter Lipton; Howard McLeod; Mark Rothstein; Helen Wallace
Pharmacogenetics: Ethical problems and solutions
Nature Reviews Genetics. 2004;5(9):676-680.28 -
252.
2004James W. Watters; Aldi Kraja; Melissa A. Meucci; Michael A. Province; Howard L. McLeod
Genome-wide discovery of loci influencing chemotherapy cytotoxicity
Proceedings of the National Academy of Sciences of the United States of America. 2004;101(32):11809-11814.84 -
253.
2004Jian-Ming Xu; Angelo Paradiso; Howard L. McLeod
European Journal of Cancer. 2004;40(12):1807-1809.10 -
254.
2004David E. Lanfear; Sharon Marsh; Howard L. McLeod; Julie A. Johnson; Taimour Y. Langaee; Issam Zineh; Amber L. Beitelshees
Caution with β1-adrenergic receptor genotyping
Clinical Pharmacology and Therapeutics. 2004;76(2):185-186.3 -
255.
2004Alex Sparreboom; Sharon Marsh; Ron H. J. Mathijssen; Jaap Verweij; Howard L. McLeod
Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients
Investigational New Drugs. 2004;22(3):285-289.12 -
256.
2004David E. Lanfear; Sharon Marsh; Sharon Cresci; William D. Shannon; John A. Spertus; Howard L. McLeod
Journal of the American College of Cardiology. 2004;44(1):165-167.15 -
257.
2004Miki Nakajima; Ryoko Yoshida; Tatsuki Fukami; Howard L. McLeod; Tsuyoshi Yokoi
Novel human CYP2A6 alleles confound gene deletion analysis
FEBS Letters. 2004;569(1-3):75-81.30 -
258.
2004Alex Sparreboom; Hans Gelderblom; Sharon Marsh; Ranjeet Ahluwalia; Rosendo Obach; Paola Principe; Chris Twelves; Jaap Verweij; Howard L. McLeod
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype
Clinical Pharmacology and Therapeutics. 2004;76(1):38-44.154 -
259.
2004Erin Quirk; Howard McLeod; William Powderly
The pharmacogenetics of antiretroviral therapy: A review of studies to date
Clinical Infectious Diseases. 2004;39(1):98-106.17 -
260.
2004Prabha Ranganathan; Robert Culverhouse; Sharon Marsh; Ranjeet Ahluwalia; William D. Shannon; Seth Eisen; Howard L. McLeod
Pharmacogenomics. 2004;5(5):559-569.27 -
261.
2004David E. Lanfear; Sharon Marsh; Sharon Cresci; John A. Spertus; Howard L. McLeod
Frequency of compound genotypes associated with β-blocker efficacy in congestive heart failure
Pharmacogenomics. 2004;5(5):553-558.6 -
262.
2004Howard L. McLeod; Cristi R. King; Sharon Marsh
Clinical Colorectal Cancer. 2004;4(SUPPL. 1):S43-S47.15 -
263.
2004Weiying Hou; James W. Watters; Howard L. McLeod
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2004;804(2):263-267.26 -
264.
2004Tao Zhao; Li-Wei Chang; Howard L. McLeod; Gary D. Stormo
PromoLign: A database for upstream region analysis and SNPs
Human Mutation. 2004;23(6):534-539.22 -
265.
2004Hiroyuki Yamanaka; Miki Nakajima; Miki Katoh; Yusuke Hara; Osamu Tachibana; Junkoh Yamashita; Howard L. McLeod; Tsuyoshi Yokoi
Pharmacogenetics. 2004;14(5):329-332.60 -
266.
2004Damon B. Rodriguez; Andrew Mackin; Roger Easley; Carolyn R. Boyle; Weiying Hou; Cory Langston; Amy M. Walsh; Michael A. Province; Howard L. McLeod
Journal of Veterinary Internal Medicine. 2004;18(3):339-345.8 -
267.
2004Mohammed T Tayeb; Caroline Clark; Neva E. Haites; Linda Sharp; Graeme I. Murray; Howard L. McLeod
Saudi Medical Journal. 2004;25(4):447-451.11 -
268.
2004Guang Xu; Wanghai Zhang; Paula Bertram; Xiao Feng Zheng; Howard McLeod
Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.
International journal of oncology. 2004;24(4):893-900.79 -
269.
2004James W. Watters; Wanghai Zhang; Melissa A. Meucci; Weiying Hou; Margaret K. Ma; Howard L. McLeod
Analysis of variation in mouse TPMT genotype, expression and activity
Pharmacogenetics. 2004;14(4):247-254.6 -
270.
2004Howard L McLeod
Current overview of pharmacogenetics.
Clinical advances in hematology & oncology : H&O. 2004;2(4):205-207.0 -
271.
2004Deepak Voora; Howard L. McLeod; Charles Eby; Brian F. Gage
Use of pharmacogenetics to guide warfarin therapy
Drugs of Today. 2004;40(3):247-257.6 -
272.
2004R.R. Freimuth; M.-M. Ameyaw; S.C. Pritchard; P.-Y. Kwok; H.L. McLeod
High-throughput genotyping methods for pharmacogenomic studies
Current Pharmacogenomics. 2004;2(1):21-33.8 -
273.
2004Howard L. McLeod
Drug pathways: Moving beyond single gene pharmacogenetics
Pharmacogenomics. 2004;5(2):139-141.15 -
274.
2004Rami G. Azrak; Shousong Cao; Harry K. Slocum; Károly Tóth; Farukh A. Durrani; Ming-Biao Yin; Lakshmi Pendyala; Wanghai Zhang; Howard L. McLeod; et al.
Therapeutic Synergy between Irinotecan and 5-Fluorouracil against Human Tumor Xenografts
Clinical Cancer Research. 2004;10(3):1121-1129.43 -
275.
200485 -
276.
2004Yixin Wang; Tim Jatkoe; Yi Zhang; Matthew G. Mutch; Dmitri Talantov; John Jiang; Howard L. McLeod; David Atkins
Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer
Journal of Clinical Oncology. 2004;22(9):1564-1571.280 -
277.
2004Daniel B Brown; Margaret K Ma; Richard J Battafarano; Sailen Naidu; Dick Pluim; William C Zamboni; Howard L McLeod
Oncology reports. 2004;11(1):237-243.3 -
278.
2004Fabienne J. Thomas; Howard L. McLeod; James W. Watters
Pharmacogenomics: The influence of genomic variation on drug response
Current Topics in Medicinal Chemistry. 2004;4(13):1399-1409.23 -
279.
2004A.K. Fukunaga; S. Marsh; D.J. Murry; T.D. Hurley; H.L. McLeod
Pharmacogenomics Journal. 2004;4(5):307-314.57 -
280.
2004Mohammed T. Tayeb; Caroline Clark; Graeme I. Murray; Linda Sharp; Neva E. Haites; Howard L. McLeod
Annals of Saudi Medicine. 2004;24(1):21-26.6 -
281.
2004Bradley D. Freeman; Howard L. McLeod
Challenges of implementing pharmacogenetics in the critical care environment
Nature Reviews Drug Discovery. 2004;3(1):88-93.10 -
282.
2004R. Mauritz; W. Schwabe; P. Haeusler; P. Noordhuis; K. Smid; H.L. McLeod; D. Behnke; C.J. Van Groeningen; G.J. Peters
Comparison of mRNA expression levels determined with Taq-man and competitive template RT-PCR
Nucleosides, Nucleotides and Nucleic Acids. 2004;23(8-9):1471-1474.5 -
283.
2004R. Mauritz; I.J. Beumer; S. Marsh; H.L. McLeod; K. Smid; C.J. Van Groeningen; H.M. Pinedo; G.J. Peters
Nucleosides, Nucleotides and Nucleic Acids. 2004;23(8-9):1381-1384.7 -
284.
2004Howard McLeod; Wan-Teck Lim
Should screening for DPD deficiency be mandatory before 5-FU exposure?
Onkologie. 2004;27(6):531-533.6 -
285.
2004Brian F. Gage; Charles Eby; Paul E. Milligan; Gerald A. Banet; Jill R. Duncan; Howard L. McLeod
Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin
Thrombosis and Haemostasis. 2004;91(1):87-94.195 -
286.
2004Howard L. McLeod; James W. Watters
Irinotecan pharmacogenetics: Is it time to intervene?
Journal of Clinical Oncology. 2004;22(8):1356-1359.38 -
287.
2003Howard L. McLeod; Mark A. Watson
Molecular therapeutics: Are we making progress?
Current Opinion in Molecular Therapeutics. 2003;5(6):573-574.0 -
288.
2003Cornelia M. Ulrich; Kim Robien; Howard L. McLeod
Cancer pharmacogenetics: Polymorphisms, pathways and beyond
Nature Reviews Cancer. 2003;3(12):912-920.107 -
289.
2003Timothy J. Ley; Patrick J. Minx; Matthew J. Walter; Rhonda E. Ries; Hui Sun; Michael McLellan; John F. DiPersio; Daniel C. Link; Michael H. Tomasson; et al.
Proceedings of the National Academy of Sciences of the United States of America. 2003;100(SUPPL. 2):14275-14280.36 -
290.
2003H. Khoury; K. Trinkaus; M.J. Zhang; D. Adkins; R. Brown; R. Vij; L.T. Goodnough; M.K. Ma; H.L. McLeod; S. Shenoy; et al.
Biology of Blood and Marrow Transplantation. 2003;9(11):714-721.12 -
291.
2003James W. Watters; Ellen F. Kloss; Daniel C. Link; Timothy A. Graubert; Howard L. McLeod
A mouse-based strategy for cyclophosphamide pharmacogenomic discovery
Journal of Applied Physiology. 2003;95(4):1352-1360.11 -
292.
2003Ranjeet Ahluwalia; Robert Freimuth; Howard L. McLeod; Sharon Marsh
Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase
Clinical Chemistry. 2003;49(10):1661-1664.20 -
293.
2003Jinsheng Yu; Sharon Marsh; Ranjeet Ahluwalia; Howard L. McLeod
Ferredoxin reductase: Pharmacogenomic assessment in colorectal cancer
Cancer Research. 2003;63(19):6170-6173.18 -
294.
2003R.D. Church; J.W. Fleshman; H.L. McLeod
Cyclo-oxygenase 2 inhibition in colorectal cancer therapy
British Journal of Surgery. 2003;90(9):1055-1067.37 -
295.
2003Ron H. J. Mathijssen; Sharon Marsh; Mats O. Karlsson; Rujia Xie; Sharyn D. Baker; Jaap Verweij; Alex Sparreboom; Howard L. McLeod
Irinotecan pathway genotype analysis to predict pharmacokinetics
Clinical Cancer Research. 2003;9(9):3246-3253.167 -
296.
2003Ramaswamy Govindan; William Read; Joan Faust; Kathryn Trinkaus; Margaret K Ma; Sharyn D Baker; Howard L McLeod; Michael C Perry
Oncology (Williston Park, N.Y.). 2003;17(9 Suppl 8):27-31.22 -
297.
2003R. Govindan; D. Behnken; W. Read; H. McLeod
Annals of Oncology. 2003;14(8):1330-1331.16 -
298.
2003S.L. Hider; C. Morgan; E. Bell; I.N. Bruce; P. Ranganathan; H.L. McLeod
Annals of the Rheumatic Diseases. 2003;62(6):591-592.6 -
299.
2003Roberto Padrini; Mariano Ferrari; Molly Carnes; Lars Noah; Richard Weinshilboum; William E. Evans; Howard L. McLeod; David B. Goldstein; Patrick Vallance
Pharmacogenetics [7] (multiple letters)
New England Journal of Medicine. 2003;348(20):2041-2043.2 -
300.
2003S. Marsh; H.L. McLeod
Crohn's disease: Ethnic variation in CARD15 genotypes [4]
Gut. 2003;52(5):770.11 -
301.
2003C. Plasencia; P.H. Rooney; M. Taron; E. Martinez-Balibrea; H.L. McLeod; A. Abad
International journal of oncology. 2003;22(5):945-953.8 -
302.
2003Weiguang Wang; Howard L. McLeod; James Cassidy
International Journal of Cancer. 2003;104(4):504-511.77 -
303.
2003M.T. Tayeb; C. Clark; N.E. Haites; L. Sharp; G.I. Murray; H.L. McLeod
British Journal of Cancer. 2003;88(6):928-932.31 -
304.
2003James W. Watters; Howard L. McLeod
Cancer pharmacogenomics: Current and future applications
Biochimica et Biophysica Acta - Reviews on Cancer. 2003;1603(2):99-111.98 -
305.
2003William E. Evans; Howard L. McLeod
Pharmacogenomics - Drug disposition, drug targets, and side effects
New England Journal of Medicine. 2003;348(6):538-549.927 -
306.
2003James W. Watters; Howard L. McLeod
Using genome-wide mapping in the mouse to identify genes that influence drug response
Trends in Pharmacological Sciences. 2003;24(2):55-58.11 -
307.
2003Howard L McLeod; Chris Papageorgio; James W Watters
Using genetic variation to optimize cancer chemotherapy.
Clinical advances in hematology & oncology : H&O. 2003;1(2):107-111.6 -
308.
2003Howard L. McLeod; Jinsheng Yu
Cancer pharmacogenomics: SNPs, chips, and the individual patient
Cancer Investigation. 2003;21(4):630-640.37 -
309.
2003P. Ranganathan; S. Eisen; W.M. Yokoyama; H.L. McLeod
Annals of the Rheumatic Diseases. 2003;62(1):4-9.56 -
310.
2003M.K. Ma; H.L. McLeod
Lessons learned from the irinotecan metabolic pathway
Current Medicinal Chemistry. 2003;10(1):41-49.51 -
311.
2003Christine M Rose; Sharon Marsh; Margaret-Mary Ameyaw; Howard L McLeod
Pharmacogenetic analysis of clinically relevant genetic polymorphisms.
Methods in molecular medicine. 2003;85:225-237.13 -
312.
2003Howard L McLeod; Robert D Church
Molecular predictors of prognosis and response to therapy in colorectal cancer.
Cancer chemotherapy and biological response modifiers. 2003;21:791-801.9 -
313.
20031 -
314.
2002S. Reif; A. Jetter; U. Fuhr; H. McLeod; D. Kingreen; W. Siegert; U. Jaehde
Population pharmacokinetics of etoposide.
International journal of clinical pharmacology and therapeutics. 2002;40(12):578-579.2 -
315.
2002Wanghai Zhang; Guang Xu; Howard L. McLeod
Applied Immunohistochemistry and Molecular Morphology. 2002;10(4):374-380.28 -
316.
2002James W. Watters; Howard L. McLeod
Recent advances in the pharmacogenetics of cancer chemotherapy
Current Opinion in Molecular Therapeutics. 2002;4(6):565-571.9 -
317.
2002Margaret K. Ma; Michael H. Woo; Howard L. McLeod
Genetic basis of drug metabolism
American Journal of Health-System Pharmacy. 2002;59(21):2061-2069.55 -
318.
2002Jill M Kolesar; Stuart C Pritchard; Keith M Kerr; Kyungman Kim; Marianne C Nicolson; Howard McLeod
International journal of oncology. 2002;21(5):1119-1124.18 -
319.
2002James W. Watters; Howard L. McLeod
Murine pharmacogenomics: Using the mouse to understand the genetics of drug therapy
Pharmacogenomics. 2002;3(6):781-790.8 -
320.
2002J.A. McKay; L.J. Murray; S. Curran; V.G Ross; C. Clark; G.I. Murray; J. Cassidy; H.L. McLeod
European Journal of Cancer. 2002;38(17):2258-2264.121 -
321.
2002C. Siva; W.M. Yokoyama; H.L. McLeod
Pharmacogenetics in rheumatology: The prospects and limitations of an emerging field
Rheumatology. 2002;41(11):1273-1279.15 -
322.
2002Attasit Boonsong; Stephanie Curran; Judith A. McKay; James Cassidy; Graeme I. Murray; Howard L. McLeod
Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases
Human Pathology. 2002;33(11):1114-1119.17 -
323.
2002G.J Peters; H.H.J Backus; S. Freemantle; B. Van Triest; G. Codacci-Pisanelli; C.L Van der Wilt; K. Smid; J. Lunec; A.H Calvert; S. Marsh; et al.
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism
Biochimica et Biophysica Acta - Molecular Basis of Disease. 2002;1587(2-3):194-205.149 -
324.
2002Howard L. McLeod
Genetic strategies to individualize supportive care
Journal of Clinical Oncology. 2002;20(12):2765-2767.6 -
325.
2002Mohammed T Tayeb; Caroline Clark; Linda Sharp; Neva E Haites; Patrick H Rooney; Graeme I Murray; Simon N L Payne; Howard L McLeod
Oncology reports. 2002;9(3):653-655.40 -
326.
2002Sharon Marsh; Judith A McKay; Stephanie Curran; Graeme I Murray; James Cassidy; Howard L McLeod
Oncology reports. 2002;9(2):231-234.21 -
327.
2002J.A. McKay; J.F. Loane; V.G. Ross; M.-M. Ameyaw; G.I. Murray; J. Cassidy; H.L. McLeod
c-erbB-2 is not a major factor in the development of colorectal cancer
British Journal of Cancer. 2002;86(4):568-573.35 -
328.
2002H.L. McLeod; M. Schwab; E. Schaeffeler; U. Brinkmann; U.M. Zanger; M. Eichelbaum
Pharmacokinetic differences between ethnic groups [6] (multiple letters)
Lancet. 2002;359(9300):78-79.8 -
329.
2002Howard L. McLeod; Chokkalingam Siva
The thiopurine S-methyltansferase gene locus - Implications for clinical pharmacogenomics
Pharmacogenomics. 2002;3(1):89-98.193 -
330.
2002Stefanie Reif; Marianne C. Nicolson; Donald Bisset; Muriel Reid; Charlotte Kloft; Ulrich Jaehde; Howard L. McLeod
Effect of grapefruit juice intake on etoposide bioavailability
European Journal of Clinical Pharmacology. 2002;58(7):491-494.42 -
331.
2002Guang Xu; Wanghai Zhang; Margaret K. Ma; Howard L. McLeod
Clinical Cancer Research. 2002;8(8):2605-2611.110 -
332.
2002Sharon Marsh; Pui Kwok; Howard L. McLeod
SNP databases and pharmacogenetics: Great start, but a long way to go
Human Mutation. 2002;20(3):174-179.45 -
333.
2002Howard L. McLeod
Individualized cancer therapy: Molecular approaches to the prediction of tumor responses
Expert Review of Anticancer Therapy. 2002;2(1):113-119.13 -
334.
2002Margaret K. Ma; Howard L. McLeod; Peter Westervelt; Paula M. Fracasso
Pharmacokinetic study of infusional valspodar
Journal of Clinical Pharmacology. 2002;42(4):412-418.2 -
335.
2002Judith A. McKay; Joy J. Douglas; Val G. Ross; Stephanie Curran; Joseph F. Loane; Fareeda Y. Ahmed; Jim Cassidy; Howard L. McLeod; Graeme I. Murray
Analysis of key cell-cycle checkpoint proteins in colorectal tumours
Journal of Pathology. 2002;196(4):386-393.62 -
336.
2002M.-M. Ameyaw; M. Tayeb; N. Thornton; G. Folayan; M. Tariq; A. Mobarek; D.A. Price Evans; D. Ofori-Adjei; H.L. McLeod
Journal of Human Genetics. 2002;47(4):172-175.40 -
337.
2001P.H. Rooney; A. Boonsong; J.A. McKay; S. Marsh; D.A.J. Stevenson; G.I. Murray; S. Curran; N.E. Haites; J. Cassidy; H.L. McLeod
Colorectal cancer genomics: Evidence for multiple genotypes which influence survival
British Journal of Cancer. 2001;85(10):1492-1498.35 -
338.
2001S. Marsh; H.L. McLeod
Thymidylate synthase pharmacogenetics in colorectal cancer.
Clinical colorectal cancer. 2001;1(3):175-178; discussion 179.65 -
339.
2001Elaina S. R. Collie-Duguid; Stephen J. Johnston; Linda Boyce; Nicola Smith; Aaron Cowieson; James Cassidy; Graeme I. Murray; Howard L. McLeod
Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer
International Journal of Cancer. 2001;94(2):297-301.23 -
340.
2001Pascal Bovet; Fred Paccaud; Howard L. McLeod; Frederick A. Masoudi; Edward P. Havranek; Elizabeth Ofili; John Flack; Gary Gibbons; Derek V. Exner; Michael J. Domanski; et al.
Race and responsiveness to drugs for heart failure [1] (multiple letters)
New England Journal of Medicine. 2001;345(10):766-768.7 -
341.
2001S. Marsh; J.A. McKay; J. Cassidy; H.L. McLeod
Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer.
International journal of oncology. 2001;19(2):383-386.155 -
342.
2001W. Wang; S. Marsh; J. Cassidy; H.L. McLeod
Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors
Cancer Research. 2001;61(14):5505-5510.52 -
343.
2001Morag C.E. McFadyen; Howard L. McLeod; Fiona C. Jackson; William T. Melvin; Johannes Doehmer; Graeme I. Murray
Cytochrome P450 CYP1B1 protein expression: A novel mechanism of anticancer drug resistance
Biochemical Pharmacology. 2001;62(2):207-212.68 -
344.
2001Andrea D. Chapman; Stuart C. Pritchard; Wan Wan Yap; Patrick H. Rooney; John S. Cockburn; Andrew W. Hutcheon; Marianne C. Nicolson; Keith M. Kerr; Howard L. McLeod
Primary pulmonary osteosarcoma: Case report and molecular analysis
Cancer. 2001;91(4):779-784.15 -
345.
2001C. Dusseau; G.I. Murray; R.A. Keenan; T. O'Kelly; H.E. Krokan; H.L. McLeod
Analysis of uracil DNA glycosylase in human colorectal cancer.
International journal of oncology. 2001;18(2):393-399.11 -
346.
2001L.C. Lawrie; S. Curran; H.L. McLeod; J.E. Fothergill; G.I. Murray
Application of laser capture microdissection and proteomics in colon cancer
Journal of Clinical Pathology - Molecular Pathology. 2001;54(4):253-258.88 -
347.
2001K. Kumagai; K. Hiyama; S. Ishioka; H. Sato; Y. Yamanishi; H.L. McLeod; F. Konishi; H. Maeda; M. Yamakido
Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese
Pharmacogenetics. 2001;11(3):275-278.69 -
348.
2001M.C.E. McFadyen; M.E. Cruickshank; I.D. Miller; H.L. McLeod; W.T. Melvin; N.E. Haites; D. Parkin; G.I. Murray
Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer
British Journal of Cancer. 2001;85(2):242-246.64 -
349.
2001H.L. McLeod; W.E. Evans
Pharmacogenomics: Unlocking the human genome for better drug therapy
Annual Review of Pharmacology and Toxicology. 2001;41:101-121.198 -
350.
2001M.-M. Ameyaw; F. Regateiro; T. Li; X. Liu; M. Tariq; A. Mobarek; N. Thornton; G.O. Folayan; J. Githang'a; A. Indalo; et al.
Pharmacogenetics. 2001;11(3):217-221.278 -
351.
2001D.A.P. Evans; H.L. Mcleod; S. Pritchard; M. Tariq; A. Mobarek
Interethnic variability in human drug responses
Drug Metabolism and Disposition. 2001;29(4 II):606-610.23 -
352.
2001Jorune Balciuniene; Anne-Christine Syvänen; Howard L. McLeod; Ulf Pettersson; Elena E. Jazin
Journal of Molecular Evolution. 2001;52(2):157-163.13 -
353.
2001D. Bissett; H.L. McLeod; B. Sheedy; M. Collier; Y. Pithavala; L. Paradiso; M. Pitsiladis; J. Cassidy
Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034
British Journal of Cancer. 2001;84(3):308-312.11 -
354.
2001Bertrand Rochat; Janine M. Morsman; Graeme I. Murray; William D. Figg; Howard L. Mcleod
Human CYP1B1 and anticancer agent metabolism: Mechanism for tumor-specific drug inactivation?
Journal of Pharmacology and Experimental Therapeutics. 2001;296(2):537-541.88 -
355.
200130 -
356.
2001G. Xu; H.L. McLeod
Strategies for enzyme/prodrug cancer therapy
Clinical Cancer Research. 2001;7(11):3314-3324.116 -
357.
2000Margaret-Mary Ameyaw; Nadia Thornton; Howard L. Mcleod
Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk [1]
Journal of the National Cancer Institute. 2000;92(23):1947.26 -
358.
2000S. Marsh; M.M. Ameyaw; J. Githang'a; A. Indalo; D. Ofori-Adjei; H.L. McLeod
Novel thymidylate synthase enhancer region alleles in African populations.
Human mutation. 2000;16(6):528.83 -
359.
2000M.M. Ameyaw; A.C. Syvänen; I. Ulmanen; D. Ofori-Adjei; H.L. McLeod
Human mutation. 2000;16(5):445-446.10 -
360.
2000R.G. Jaffrey; S.C. Pritchard; C. Clark; G.I. Murray; J. Cassidy; K.M. Kerr; M.C. Nicolson; H.L. McLeod
Genomic instability at the BUB1 locus in colorectal cancer, but not in non-small cell lung cancer
Cancer Research. 2000;60(16):4349-4352.21 -
361.
2000Attasit Boonsong; Sharon Marsh; Patrick H. Rooney; David A.J. Stevenson; James Cassidy; Howard L. McLeod
Characterization of the topoisomerase I locus in human colorectal cancer
Cancer Genetics and Cytogenetics. 2000;121(1):56-60.19 -
362.
2000H.L. McLeod; J.A. McKay; E.S.R. Collie-Duguid; J. Cassidy
Therapeutic opportunities from tumour biology in metastatic colon cancer
European Journal of Cancer. 2000;36(13):1706-1712.28 -
363.
2000J.A. McKay; C. Lloret; G.I. Murray; P.G. Johnston; R. Bicknell; F.Y. Ahmed; J. Cassidy; H.L. McLeod
International journal of oncology. 2000;17(1):153-158.13 -
364.
2000Howard L. McLeod; James Cassidy; Robert H. Powrie; David G. Priest; Mark A. Zorbas; Timothy W. Synold; Stephen Shibata; Darcy Spicer; Donald Bissett; et al.
Clinical Cancer Research. 2000;6(7):2677-2684.15 -
365.
2000E.S.R. Collie-Duguid; S.J. Johnston; R.H. Powrie; G. Milano; M.C. Etienne; B. Rochat; G.C. Watson; H.L. McLeod
Cloning and initial characterization of the human DPYD gene promoter
Biochemical and Biophysical Research Communications. 2000;271(1):28-35.23 -
366.
2000Judith A. McKay; Joy J. Douglas; Val G. Ross; Stephanie Curran; Fareeda Y. Ahmed; Joseph F. Loane; Graeme I. Murray; Howard L. McLeod
Clinical Cancer Research. 2000;6(3):1113-1118.43 -
367.
2000H.L. McLeod; E.Y. Krynetski; M.V. Relling; W.E. Evans
Leukemia. 2000;14(4):567-572.266 -
368.
2000Elaina S.R. Collie-Duguid; M.C. Etienne; G. Milano; H.L. McLeod
Known variant DPYD alleles do not explain DPD deficiency in cancer patients
Pharmacogenetics. 2000;10(3):217-223.139 -
369.
2000S. Curran; J.A. McKay; H.L. McLeod; G.I. Murray
Journal of Clinical Pathology - Molecular Pathology. 2000;53(2):64-68.79 -
370.
2000G. Milano; H.L. McLeod
Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?
European Journal of Cancer. 2000;36(1):37-42.49 -
371.
2000E.S.R. Collie-Duguid; H.L. McLeod; J. Cassidy
Estimation of dihydropyrimidine dehydrogenase activity: Does it have a role in cancer therapy?
Annals of Oncology. 2000;11(3):255-257.3 -
372.
2000John D. Roberts; Stephen Shibata; Darcy V. Spicer; Howard L. McLeod; Mary Beth Tombes; Brenda Kyle; Mary Carroll; Beth Sheedy; Mary A. Collier; et al.
Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks
Cancer Chemotherapy and Pharmacology. 2000;45(5):423-427.10 -
373.
2000J.M. Morsman; H.L. McLeod
Taxane chemotherapy and new microtubule-interactive agents
Current Opinion in Oncologic, Endocrine and Metabolic Investigational Drugs. 2000;2(3):305-311.5 -
374.
2000Judith A. McKay; Joy J. Douglas; Val G. Ross; Stephanie Curran; Graeme I. Murray; Jim Cassidy; Howard L. McLeod
Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas
International Journal of Cancer. 2000;88(1):28-36.66 -
375.
2000Janine M. Morsman; Julieann Sludden; Margaret-Mary Ameyaw; Jessie Githang'A; Anne Indalo; David Ofori-Adjei; Howard L. McLeod
British Journal of Clinical Pharmacology. 2000;50(3):269-272.14 -
376.
2000D. Bissett; F. Ahmed; H. McLeod; J. Cassidy
Oral fluoropyrimidines in the treatment of colorectal cancer
Clinical Oncology. 2000;12(4):240-245.6 -
377.
2000Catherine Terret; Eric Erdociain; Rosine Guimbaud; Michèle Boisdron-Celle; Howard L McLeod; Régine Féty-Deporte; Thierry Lafont; Erick Gamelin; Roland Bugat; et al.
Dose and time dependencies of 5-fluorouracil pharmacokinetics
Clinical Pharmacology and Therapeutics. 2000;68(3):270-279.27 -
378.
2000M.T. Tayeb; C. Clark; M.-M. Ameyaw; N.E. Haites; D.A.P. Evans; M. Tariq; A. Mobarek; D. Ofori-Adjei; H.L. McLeod
CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations
Pharmacogenetics. 2000;10(8):753-756.24 -
379.
1999Francesco Caponigro; Antonio Avallone; Howard McLeod; Giacomo Cartenì; Ferdinando De Vita; Rossana Casaretti; Janine Morsman; Robert Blackie; Alfredo Budillon; Luigi De Lucia; et al.
Clinical Cancer Research. 1999;5(12):3948-3955.19 -
380.
1999Shinichi Ishioka; Keiko Hiyama; Hiroe Sato; Yuji Yamanishi; Howard L. McLeod; Kazuhiko Kumagai; Hiroyuki Maeda; Michio Yamakido
Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese
Internal Medicine. 1999;38(12):944-947.42 -
381.
1999H.L. McLeod; G.I. Murray; J. Mollison; J. McKay; J. Cassidy
Selection of markers to predict tumour response or survival: Description of a novel approach
European Journal of Cancer. 1999;35(12):1650-1652.11 -
382.
1999Stephen J. Johnston; Susan A. Ridge; James Cassidy; Howard L. McLeod
Regulation of dihydropyrimidine dehydrogenase in colorectal cancer
Clinical Cancer Research. 1999;5(9):2566-2570.68 -
383.
1999Fareeda Y. Ahmed; Stephen J. Johnston; James Cassidy; Terry O'Kelly; Norman Binnie; Graeme I. Murray; Albert H. van Gennip; Nico G.G.M. Abeling; Sidonie Knight; Howard L. McLeod
Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors
Journal of Clinical Oncology. 1999;17(8):2439-2445.46 -
384.
1999Sharon Marsh; Elaina S. R. Collie-Duguid; Tao Li; Xiehe Liu; Howard L. McLeod
Genomics. 1999;58(3):310-312.151 -
385.
1999H.L. McLeod; W.E. Evans
Oral cancer chemotherapy: The promise and the pitfalls
Clinical Cancer Research. 1999;5(10):2669-2671.25 -
386.
1999Margaret-Mary Ameyaw; Elaina S.R. Collie-Duguid; Robert H. Powrie; David Ofori-Adjei; Howard L. McLeod
Thiopurine methyltransferase alleles in British and Ghanaian populations
Human Molecular Genetics. 1999;8(2):367-370.169 -
387.
1999E.S.R. Collie-Duguid; S.C. Pritchard; R.H. Powrie; J. Sludden; D.A. Collier; T. Li; H.L. McLeod
Pharmacogenetics. 1999;9(1):37-42.208 -
388.
1999H.L. McLeod; G.I. Murray
Tumour markers of prognosis in colorectal cancer
British Journal of Cancer. 1999;79(2):191-203.168 -
389.
1999P.H. Rooney; G.I. Murray; D.A.J. Stevenson; N.E. Haites; J. Cassidy; H.L. McLeod
Comparative genomic hybridization and chromosomal instability in solid tumours
British Journal of Cancer. 1999;80(5-6):862-873.83 -
390.
1999Howard L. McLeod; Sally Coulthard; Angela E. Thomas; Stuart C. Pritchard; Derek J. King; Susan M. Richards; O.B. Eden; Andrew G. Hall; Brenda E.S. Gibson
Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia
British Journal of Haematology. 1999;105(3):696-700.91 -
391.
1999Howard L. McLeod; Stuart C. Pritchard; Jessie Githang'a; Anne Indalo; Margaret-Mary Ameyaw; Robert H. Powrie; Lynne Booth; Elaina S.R. Collie-Duguid
Pharmacogenetics. 1999;9(6):773-776.116 -
392.
1998Patrick H. Rooney; David A. J. Stevenson; Sharon Marsh; Patrick G. Johnston; Neva E. Haites; James Cassidy; Howard L. McLeod
Cancer Research. 1998;58(22):5042-5045.33 -
393.
1998Alison J. Black; Howard L. McLeod; Hillary A. Capell; Robert H. Powrie; Lloyd K. Matowe; Stuart C. Pritchard; Elaina S.R. Collie-Duguid; David M. Reid
Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine
Annals of Internal Medicine. 1998;129(9):716-718.262 -
394.
1998H.L. McLeod; J. Sludden; S.C. Hardy; R.E. Lock; G.M. Hawksworth; J. Cassidy
Autoregulation of 5-fluorouracil metabolism
European Journal of Cancer. 1998;34(10):1623-1627.36 -
395.
1998Xiaoxiong Wei; Guillermo Elizondo; Andrea Sapone; Howard L. McLeod; Hannu Raunio; Pedro Fernandez-Salguero; Frank J. Gonzalez
Characterization of the human dihydropyrimidine dehydrogenase gene
Genomics. 1998;51(3):391-400.98 -
396.
1998Julieann Sludden; Sarah C. Hardy; Mark R. VandenBranden; Steven A. Wrighton; Howard L. McLeod
Pharmacology. 1998;56(5):276-280.8 -
397.
1998S.A. Ridge; J. Sludden; X. Wei; A. Sapone; O. Brown; S. Hardy; P. Canney; P. Fernandez-Salguero; F.J. Gonzalez; J. Cassidy; et al.
Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer
British Journal of Cancer. 1998;77(3):497-500.81 -
398.
1998H.L. McLeod; J. Sludden; G.I. Murray; R.A. Keenan; A.I. Davidson; K. Park; M. Koruth; J. Cassidy
Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours
British Journal of Cancer. 1998;77(3):461-465.105 -
399.
1998Howard L. McLeod; Ann-Christine Syvänen; Jessie Githang'a; Anne Indalo; Debbie Ismail; Kevin Dewar; Ismo Ulmanen; Julieann Sludden
Pharmacogenetics. 1998;8(3):195-199.42 -
400.
1998Howard L. McLeod; Christine M. Kearns; John G. Kuhn; Rene Bruno
Evaluation of the linearity of docetaxel pharmacokinetics
Cancer Chemotherapy and Pharmacology. 1998;42(2):155-159.28 -
401.
1998Howard L. McLeod
Clinically relevant drug-drug interactions in oncology
British Journal of Clinical Pharmacology. 1998;45(6):539-544.46 -
402.
1998H.L. McLeod; E.S.R. Collie-Duguid; P. Vreken; M.R. Johnson; X. Wei; A. Sapone; R.B. Diasio; P. Fernandez-Salguero; A.B.P. Van Kuilenberg; et al.
Nomenclature for human DPYD alleles
Pharmacogenetics. 1998;8(6):455-459.75 -
403.
1998Susan A. Ridge; Julieann Sludden; Oliver Brown; Leigh Robertson; Xiaoxiong Wei; Andrea Sapone; Pedro M. Fernandez-Salguero; Frank J. Gonzalez; Peter Vreken; Andre B.P. Van Kuilenburg; et al.
Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects
British Journal of Clinical Pharmacology. 1998;46(2):151-156.98 -
404.
1998Lisa Bomgaars; Howard L. McLeod
Pharmacogenetics and pediatric cancer
Cancer Journal. 1998;11(4):314-323.0 -
405.
1997J. Boyle; D. Henderson; J. McCall; H. McLeod; J. Usher
Exploring novel chemotherapy treatments using the WWW
International Journal of Medical Informatics. 1997;47(1-2):107-114.3 -
406.
1997Wiboon Wattanatorn; Howard L. McLeod; Fiona Macklon; Muriel Reid; Keith E. Kendle; James Cassidy
Pharmacotherapy. 1997;17(5 I):881-886.7 -
407.
1997W. Wattanatorn; H.L. McLeod; J. Cassidy; K.E. Kendle
Journal of Chromatography B: Biomedical Applications. 1997;692(1):233-237.21 -
408.
1997S.A. Ridge; O. Brown; J. McMurrough; P. Fernandez-Salguero; W.E. Evans; F.J. Gonzalez; H.L. McLeod
Mutations at codon 974 of the DPYD gene are a rare event
British Journal of Cancer. 1997;75(2):178-179.7 -
409.
1997Judith A. McKay; Graeme I. Murray; W. Nicol Keith; Howard L. McLeod
Journal of Clinical Pathology - Molecular Pathology. 1997;50(6):322-325.18 -
410.
1997Howard L. McLeod
Therapeutic drug monitoring opportunities in cancer therapy
Pharmacology and Therapeutics. 1997;74(1):39-54.17 -
411.
1996Xiaoxiong Wei; Howard L. McLeod; Julieann McMurrough; Frank J. Gonzalez; Pedro Fernandez-Salguero
Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity
Journal of Clinical Investigation. 1996;98(3):610-615.238 -
412.
1996H.L. McLeod; M.A. Graham; S. Aamdal; A. Setanoians; Y. Groot; B. Lund
Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9
European Journal of Cancer Part A. 1996;32(9):1518-1522.17 -
413.
1996H.L. McLeod; V.G. Brunton; N. Eckardt; M.J. Lear; D.J. Robins; P. Workman; M.A. Graham
In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022
British Journal of Cancer. 1996;74(11):1714-1718.15 -
414.
19960 -
415.
1996J. Mcmurrough; H.L. Mcleod
Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population
British Journal of Clinical Pharmacology. 1996;41(5):425-427.38 -
416.
1996G.P. Connolly; H.A. Simmonds; J.A. Duley; H.L. McLeod; P. Fernandez-Salguero; F.J. Gonzalez
Pyrimidines and CNS regulation
Trends in Pharmacological Sciences. 1996;17(3):106-107.14 -
417.
1996H.L. McLeod; M.A. Graham; S. Aamdal; A. Setanoians; Y. Groot; B. Lund
Phase i pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug eo9
European Journal of Cancer Part A. 1996;32(9):1504-1509.1 -
418.
1996H.L. McLeod; L.S. Murray; J. Wanders; A. Setanoians; M.A. Graham; N. Pavlidis; B. Heinrich; W.W. Ten Bokkel Huinink; D.J.Th. Wagener; et al.
Multicentre phase II pharmacological evaluation of rhizoxin
British Journal of Cancer. 1996;74(12):1944-1948.23 -
419.
1996H.L. McLeod; W.N. Keith
Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity
British Journal of Cancer. 1996;74(4):508-512.46 -
420.
1995Howard L. McLeod; Eugene Y. Krynetski; Judith A. Wilimas; William E. Evans
Pharmacogenetics. 1995;5(5):281-286.46 -
421.
1995H.L. McLeod; R. Capdeville; B. Mousson; G. Bax
European Journal of Clinical Pharmacology. 1995;48(1):85-88.4 -
422.
1995H.L. McLeod; M.V. Relling; Q. Liu; C.-H. Pui; W.E. Evans
Blood. 1995;85(7):1897-1902.142 -
423.
1995J. Cassidy; H.L. McLeod
Is it possible to design a logical development plan for an anti-cancer drug?
Pharmaceutical Medicine. 1995;9(2):95-103.7 -
424.
1995H.L. McLeod; M.V. Relling; Liu Qing; Pui Ching-Hon; W.E. Evans
Blood. 1995;85(7):187-902.29 -
425.
1994Dave Hollander; Jesus Pradas; Richard Kaplan; Howard L. McLeod; William E. Evans; Theodore L. Munsat
Annals of Neurology. 1994;36(6):920-924.50 -
426.
1994H.L. McLeod; J.-S. Lin; E.P. Scott; C.-H. Pui; W.E. Evans
Thiopurine methyltransferase activity in American white subjects and black subjects
Clinical Pharmacology and Therapeutics. 1994;55(1):15-20.181 -
427.
1994H.L. McLeod; M. Dahl; A. Llerena; J. Cobaleda; A. Harraiz; I. Johansson
Concordance of phenotype and genotype for CYP2D6 [1]
Clinical Pharmacology and Therapeutics. 1994;56(4):463-464.3 -
428.
1994Mary V. Relling; Howard L. McLeod; Laura C. Bowman; Victor M. Santana
Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin
Clinical Pharmacology and Therapeutics. 1994;56(5):503-511.36 -
429.
1994H.L. McLeod; F. Douglas; M. Oates; R.P. Symonds; D. Prakash; A.G.J. van der Zee; S.B. Kaye; R. Brown; W.N. Keith
Topoisomerase I and II activity in human breast, cervix, lung and colon cancer
International Journal of Cancer. 1994;59(5):607-611.70 -
430.
1994H.L. McLeod; L. Fang; X. Luo; E.P. Scott; W.E. Evans
Ethnic differences in erythrocyte catechol-O-methyltransferase activity in black and white Americans
Journal of Pharmacology and Experimental Therapeutics. 1994;270(1):26-29.47 -
431.
1994H.L. McLeod
European Journal of Cancer Part A: General Topics. 1994;30(14):2039-2041.19 -
432.
1993W.E. Evans; M.V. Relling; A. Rahman; H.L. McLeod; E.P. Scott; J.-S. Lin
Journal of Clinical Investigation. 1993;91(5):2150-2154.69 -
433.
1993H.L. McLeod; D.R. Miller; W.E. Evans
Lancet. 1993;341(8853):1151.87 -
434.
1993J.H. Rodman; M.V. Relling; C.F. Stewart; T.W. Synold; H. McLeod; C. Kearns; N. Stute; W.R. Crom; W.E. Evans
Clinical pharmacokinetics and pharmacodynamics of anticancer drugs in children
Seminars in Oncology. 1993;20(1):18-29.27 -
435.
1993H.L. McLeod; W.E. Evans
Clinical pharmacokinetics and pharmacodynamics of epipodophyllotoxins
Cancer Surveys. 1993;17:253-268.15 -
436.
1992H.L. McLeod; W.E. Evans
Pediatric pharmacokinetics and therapeutic drug monitoring.
Pediatrics in Review. 1992;13(11):413-421.10 -
437.
1992H.L. McLeod; M.V. Relling
Stability of etoposide solution for oral use
American Journal of Hospital Pharmacy. 1992;49(11):2784-2785.8 -
438.
1992H.L. McLeod; T.R. McGuire; G.C. Yee
Annals of Pharmacotherapy. 1992;26(2):172-175.4 -
439.
1992H.L. McLeod; M.V. Relling; W.R. Crom; K. Silverstein; S. Groom; J.H. Rodman; G.K. Rivera; W.M. Crist; W.E. Evans
Disposition of antineoplastic agents in the very young child
British Journal of Cancer. 1992;66(SUPPL. 18):S23-S29.43 -
440.
1991H.L. McLeod; D.K. Baker Jr.; C.-H. Pui; J.H. Rodman
Cancer Chemotherapy and Pharmacology. 1991;29(2):150-154.4
